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Chronic pain affects between 20 and 30 percent of the adult population in western countries and
represents a wide array of specific etiologies (Berge, 2011). Neuropathic pain secondary to
traumatic nerve injury, chemotherapeutic toxicity, or diseases (e.g., diabetes mellitus) is often
refractory to conventional analgesics, with patients receiving less than 50% pain relief compared
to placebo (Finnerup et al. 2010). The endocannabinoid system has shown potential as a
therapeutic target for neuropathic pain wherein CB1 agonism via administration of exogenous
agonists or pharmacological blockade of endocannabinoid catabolic enzymes exhibits efficacy in
reversing allodynia in the chronic constriction injury (CCI) model of neuropathic pain (Rahn &
Hohmann, 2009). More recently CB1 positive allosteric modulators (PAMs) have shown
antinociceptive efficacy in CCI with ZCZ011 and its analogs, GAT211 and ABD1236,
producing dose and time-dependent reversal of allodynia (Ignatowska-Jankowska et al. 2015;
Slivicki et al. 2018; Tseng et al. 2019). This study reports the activity of the 2-phenyl indole

class of CB1 PAMs represented by ZCZ011 in behavioral paradigms for overt and subjective
cannabimimetic side effects, and neuropathic pain. The goal of the study was to examine the
relationship between the antiallodynic effects, overt and subjective cannabimimetic effects of
CB1 PAMs. Overt cannabimimetic activity was assessed in the tetrad assay which consists of the
measures: locomotor activity, catalepsy, antinociception, and hypothermia). Subjective
cannabimimetic effects were measured in the drug discrimination paradigm. ZCZ011 analogs
were either tested alone in these assays to screen for agonist activity or in combination with CB1
orthosteric agonist CP55,940 to screen for PAM effects. ZCZ011 analogs did not exhibit CB1
agonist activity as measured in the tetrad assay and drug discrimination paradigm when
administered alone. ZCZ011 was the only PAM to potentiate all three measures of the triad assay
(catalepsy, antinociception, hypothermia) whereas the remaining analogs potentiated only a
subset of those effects. ZCZ011, GAT211, LDK1747, and LDK1752 were evaluated in the drug
discrimination paradigm. Of these compounds only ZCZ011 and LDK1752 had a potentiating
effect on subjective responding to CP55,940. Lastly ZCZ011 analogs were tested for
antiallodynic activity in a chronic constriction injury (CCI) model of neuropathic pain. ZCZ011,
ABD1236, and GAT211 produced full reversal of allodynia in CCI-mice whereas the remaining
analogs had no effect. Comparing results from this study, ZCZ011 is the only compound which
exhibits PAM activity in each of the three behavioral paradigms. The remaining analogs show
disparate effects with respect to overt and/or subjective cannabimimetic effects and antiallodynic
activity. The results of this study indicate that there is no correlation for CB1 PAM activity
between the three behavioral paradigms and that it is possible for CB1 PAMs to affect only a
subset of cannabinoid-related behaviors.

Chapter 1. General Introduction

Endogenous Cannabinoid System

Endogenous Cannabinoid Receptors
Cannabinoid receptors are highly conserved in vertebrates and have also been identified
in some invertebrate species (Elphick, 2012; McPartland, 2004). Human and rodent CB1
receptors have a high degree of sequence similarity sharing greater than 90% nucleic acid
identity and 97% amino acid identity (Abood et al. 1997; Chakrabarti et al. 1995; Ho & Zhao,
1996). A strong line of evidence for the existence of cannabinoid receptors came from studies
showing that cannabinoids inhibit adenylyl cyclase activity in neuronal cell models (Howlett &
Fleming, 1984). The cannabinoid type-1 (CB1) receptor was then identified through radioligand
binding studies using [3H]-CP55,940 and subsequently cloned from rat and human brain (Devane
et al. 1988; Gérard et al. 1991; Matsuda et al. 1990). A second subtype, cannabinoid type-2
(CB2) receptor was identified and cloned using a PCR-based approach in differentiated myeloid
cell lines (Munro et al. 1993). Both CB1 and CB2 receptors are the primary targets of ∆9-THC,
the primary psychoactive constituent of Cannabis sativa (Rinaldi-Carmona et al. 1994). In
conjunction with receptor binding data, in vivo behavioral measures such as the tetrad assay and
drug discrimination paradigm have helped confirm that CB1 receptors mediate the effects of
cannabinoids in the CNS (Compton et al. 1993; Wiley et al. 1995a-c).

Anatomic Distribution of Cannabinoid Receptors
The CB1 receptor is the most highly expressed G-protein coupled receptor (GPCR) in the
CNS, with highest expression in the cerebral cortex, cerebellum, hippocampus, and basal ganglia
nuclei (Glass et al. 1997; Herkenham et al. 1990; Tsou et al. 1998). The effects of cannabinoids
on memory and cognition, motor control, and analgesia are correlated with the distribution of
CB1 receptors in the cerebral cortex and hippocampus, cerebellum, and basal ganglia,
respectively. CB1 receptors are expressed presynaptically on GABAergic neurons and to a lesser
extent on glutamatergic neurons where the mediate inhibition of neurotransmitter release
(Katona et al. 1999; Puighermanal et al. 2009; Straiker & Mackie, 2005). CB1 receptors are also
expressed in astrocytes where they play a role in modulating synaptic transmission and plasticity
(Han et al. 2012). In the periphery, CB1 receptors are expressed in circulating immune cells and
several tissues including adrenal gland, bone marrow, heart, liver, lung, prostate, ovary, testis,
thymus, tonsil, uterus, and vas deferens (Bouaboula et al. 1999; Galiegue et al. 1995). The CB2
receptor is mainly expressed in cells associated with immune system function including lung,
spleen, testis, thymus, tonsil, leukocytes and macrophages (Brown et al. 2002; Galiegue et al.
1995; Munro et al. 1993). In the CNS, CB2 receptors are primarily expressed in microglia and
are upregulated during immune responses to stimulate chemotactic responding (Cabral et al.
2008; Palazuelos et al. 2009). CB2 expression has also been reported in neuronal cells where
they may modulate dopamine-related behaviors in mice as well as synaptic plasticity in
hippocampal neurons (Stempel et al. 2016; Zhang et al. 2014; Xi et al. 2011).

Endocannabinoids
The discovery of cannabinoid receptors prompted research efforts to identify the putative
endogenous ligands of CB1 and CB2. The first candidate molecule was Narachidonoylethanolamine (anandamide; AEA), isolated from porcine brain, which was shown to
displace [3H]-U243 from rat membranes and inhibit electrically contractions of isolated mouse
vas deferens (Devane et al. 1992). The second endocannabinoid identified was 2-arachidonoyl
glycerol (2-AG). Similar to AEA, 2-AG was found to displace synthetic cannabinoids in
competitive inhibition experiments and also produced tetrad effects in vivo when administered
exogenously (Mechoulam et al. 1995; Sugiura et al. 1995). Arachidonic acid and Npalmitoylethanolamine lack cannabimimetic activity indicating that free arachidonic acid, of
which AEA and 2-AG are precursors, does not activate cannabinoid receptors and that the
arachidonic acid moiety is required of N-acylethanolamines and N-acylglycerols for receptor
activation (Sugiura et al. 1995). Hence, AEA and 2-AG are degraded enzymatically and
represent the putative endogenous ligands of cannabinoid receptors. Both the synthesis and
degradation of endocannabinoids are subject to enzymatic regulation. AEA is synthesized by Nacyl phosphatidylethanolamine-specific phospholipase D (NAPE-PLD) (Cadas et al. 1996;
Schmid et al. 1983). 2-AG is synthesized by diacylglycerol lipase (DAGL), of which there exists
two isoforms: DAGLα, expressed in neuronal cells and DAGLß, expressed in microglia and
macrophages (Bell et al. 1979; Prescott & Majerus 1983; Viader et al. 2016). In neuronal cells,
the endocannabinoids are synthesized on demand from membrane phospholipids and signal
retrograde to CB1 receptors on the presynaptic membrane to inhibit neurotransmitter release
(Bisogno et al. 2003; Katona et al. 2006). AEA and 2-AG are subsequently degraded by fatty

acid amide hydrolase (FAAH) and monoacylglycerol lipase (MAGL), respectively (Gulyas et al.
2004; Nyilas et al. 2008; Pan et al. 2011; Zhong et al. 2011).

Cannabinoid Pharmacology

Cannabinoid Receptor Structure and Binding Sites
The CB1 and CB2 receptors belong to the G-protein coupled receptor (GPCR) family and
are primarily coupled to Gαi/o heterotrimeric G proteins but also signal through ß-arrestins
(Howlett et al. 1985; Jin et al. 1999). The crystal structures of CB1 and CB2 have been obtained
in complex with stabilizing antagonists AM6538 and AM10257, respectively (Hua et al. 2016,
Li et al. 2019). Characteristic of GPCRs, cannabinoid receptors possess seven transmembrane
domains connected by three extracellular and intracellular loops each, an extracellular Nterminal tail, and an intracellular C-terminal tail. Extracellular loop 2 (ECL2) of CB1 is notably
involved in agonist/inverse agonist binding (Ahn et al. 2009). Docking studies have shown that
CB1 agonists including AEA, 2-AG, ∆9-THC, CP55,940, JWH-018, and WIN55,212-2 interact
mainly with ECL2, the N-terminal loop, and transmembrane helices III, VI, and VII (Hua et al.
2016). Together these domains make up the orthosteric binding site which recognizes agonist
and inverse agonist ligands. In addition to the orthosteric binding site, other allosteric binding
sites have been identified on CB1 receptors (Hurst et al. 2019; Shao et al. 2019). Studies on CB2
receptors have identified various similarities and differences between CB1 and CB2 receptors
which help to explain differences in selectivity of cannabinoid receptor agonists and antagonists
(Li et al. 2019). The CB2 receptor also possesses multiple binding sites as evidenced by reports
on selective CB2 allosteric modulators (Gado et al. 2019).

Cannabinoid Receptor Signaling Pathways
GPCR signaling occurs in three separate spatiotemporal waves (Lohse & Hofmann, 2015;
Nogueras-Ortiz & Yudowski, 2016). The first wave of CB1 signaling is mediated through Gαi/o
which leads to decreased cAMP through inhibition of adenylyl cyclase, decreased Ca2+
conductance, and increased K+ conductance (Mackie et al. 1995; Twitchell et al. 1997; Guo &
Ikeda, 2004). The second wave occurs after ligand-induced receptor phosphorylation which leads
to receptor desensitization and ß-arrestin recruitment. ß-arrestins in this wave of signaling
function in receptor internalization as well as activation of several downstream effectors (Ahn et
al. 2013; Breivogel et al. 2008; Delgado-Peraza et al. 2016; Laprairie et al. 2014). The third
wave of cannabinoid signaling is mediated through CB1 receptors localized to intracellular
compartments (Brailoiu et al. 2011; Rozenfeld & Devi, 2008).

Allosteric Modulation of Cannabinoid Type I Receptors

Allosteric Modulation and Biased Signaling
The operational model of receptor theory (Eq. 1.1) holds that a pharmacological response
is given by the concentration of agonist, its dissociation constant for the receptor, the maximal
response, and a tissue-specific component 𝜏 which represents the concentration of agonist bound
receptor that produces a half-maximal tissue response (Black & Leff, 1983; Kenakin, 2004). The
operational model allows for comparison of agonist responses between different receptor
systems. The site to which an agonist binds a receptor to elicit a response is termed the

orthosteric site. Allosteric modulators bind to topologically distinct or allosteric sites where they
induce conformational changes that alter receptor activity (Kenakin, 2004).

Response = ([A] x 𝜏 x EMax) / ([A](𝜏+1) + KA

Equation 1.1

To understand allosteric modulation of GPCRs one must take into account ligand binding
at both orthosteric and allosteric sites, receptor activation states, and G protein
association/activation. Models for the biochemical mechanisms of GPCRs include the extended
ternary complex (ETC) model and cubic ternary complex (CTC) model (De Lean et al. 1980;
Weiss et al. 1996). The ETC and CTC models are shown in Figure 1.1. In the ETC model the
receptor can exist in an active (Ra) or inactive state (Ri). These receptor states may coexist
according to the allosteric constant L given by L = [Ra] / [Ri]. Constitutive receptor activity is
given by the concentration of active state RaG species. Allosteric modulators can then, according
to this model, affect receptor activity through changes in receptor affinity towards orthosteric
ligands or G proteins; that is allosteric modulators may affect both affinity and efficacy
(Kenakin, 2013). Not shown in the ETC or CTC model is the association of the receptor with ßarrestins which mediate arrest of G protein signaling, receptor internalization, and intracellular
signaling (Lefkowitz et al. 1998; Lohse et al. 1990; Luttrell et al. 1999). Allosteric modulators
may impart bias towards either G protein or ß-arrestin signaling in the presence of an orthosteric
agonist, which even alone may exhibit signaling bias (Kenakin, 2019).

A. Extended ternary complex (ETC) model

B. Cubic ternary complex (CTC)
model

Figure 1.1 Pictorial representations of the extended ternary complex (ETC) model (A) and the
cubic ternary complex (CTC) model (B). Figures drawn by author using ChemDraw
Professional 16.0. 1.4

CB1 Negative Allosteric Modulators
Org27569, Org27759, and Org29647 were the first CB1 allosteric modulators
characterized. These compounds were shown to increase the binding of [3H]-CP55,940 but
caused significant reductions in the EMax values for CP55,940- and AEA-induced [35S] GTPS
binding (Baillie et al. 2013; Price et al.2005). Despite enhancement of orthosteric agonist
binding, the decrease in CB1 signaling functionally classifies these compounds as negative
allosteric modulators (NAMs) of CB1 receptors. Org27569 reduces inhibition of cAMP
accumulation for several natural and synthetic CB1 agonists (Khajehali et al. 2015). Org27569
also reduces CP55,940-induced ß-arrestin recruitment and downstream signaling (Ahn et al.

2012). In vivo Org27569 decreases feeding behavior in rats and mice, as well as decreases
CP55,940-induced hypothermia in rats in the triad assay (Gamage et al. 2014; Ding et al. 2014).
CB1 NAMs have also been studied in the drug discrimination paradigm (see Chapter 2).

CB1 Positive Allosteric Modulators
Using in vivo measures such as the tetrad assay and drug discrimination paradigm, CB1
PAMs have been shown to augment the overt and subjective cannabimimetic effects of
orthosteric CB1 agonists but lack intrinsic activity in these assays when administered alone
(Table 1.2).Three classes of CB1 positive allosteric modulators (PAMs) include the tropane
derivatives (analogs of RTI-371), lipoxin A4, and 2-phenyl indoles (analogs of ZCZ011)
(Ignatowska-Jankowska et al. 2015; Navarro et al. 2009; Pamplona et al. 2012). In contrast to
CB1 NAMs, these compounds enhance both the binding and signaling of orthosteric agonists.
ZCZ011 is fairly well characterized both in vitro and in vivo and several of its analogs have been
tested in the CCI model of neuropathic pain, tetrad/triad assay, and drug discrimination paradigm
(Table 1.1. and 1.2). Compounds including ZCZ011, GAT211, and ABD1236 have
demonstrated antiallodynic effects in models of neuropathic pain (Ignatowska-Jankowska et al.
2015; Slivicki et al. 2018; Tseng et al. 2019). The LDK series of ZCZ011 analogs lack
antiallodynic activity but demonstrate some PAM activity with CP55,940 in the triad assay. In
drug discrimination, only ZCZ011 has been studied where it has been shown to potentiate the
subjective effects of AEA and CP55,940. The subjective drug effects of the remaining analogs
have yet to be evaluated.

The Endogenous Cannabinoid System in Acute and Chronic Pain

Ascending and Descending Pain Pathways
The spinothalamic and spinoparabrachial tracts are two major ascending pathways in
mammals, which relay noxious stimulation (Sun et al. 2020; Yam et al. 2018). Nociception is
relayed through a series of neurons starting with primary sensory afferents which originate in the
periphery and run through the dorsal root ganglion (DRG) into the dorsal horn of the spinal cord
where they synapse with second-order neurons. These second-order neurons decussate in the
spinal cord, ascend the contralateral ventral column then synapse with third-order neurons in the
thalamus. Finally, the third-order neurons project to the primary somatosensory cortex of the
postcentral gyrus. The spinoparabrachial tract originates in the spinal cord and relays pain
information to the parabrachial nuclei of the pons where the synapse with third-order neurons
which then project to the hypothalamus and amygdala which mediate the emotional response to
pain. Modulation of pain is mediated by the descending pain pathway, which originates in the
cortex, hypothalamus, and amygdala and projects down through the brainstem and spinal cord
via the periaqueductal grey (PAG). The endocannabinoid system is expressed throughout both
ascending and descending pain pathways and modulates pain through peripheral, spinal, and
supraspinal mechanisms of action. CB1 receptors are expressed by primary afferent neurons on
their peripheral endings, central terminals, and in the DRG (Hohmann et al. 1999; Hohmann &
Herkham 1998, 1999a). In the spinal cord, CB1 receptors are located within the superficial
laminae of the dorsal horn (Glass et al. 1997; Tsou et al. 1998). In the brain, CB1 receptors are
found in all brain regions associated with pain processing including the cerebral cortex,
thalamus, hypothalamus, amygdala, basal ganglia, and PAG (Glass et al. 1997). CB2 receptors

have also been found in the same brain regions involved in pain as the CB1, although to a lesser
extent (Brusco et al. 2008; Gong et al. 2006; Onaivi et al. 2006). Lastly, the biosynthetic and
degradative enzymes of the endocannabinoids are expressed throughout both ascending and
descending pain pathways in tissues innervated by primary afferents as well as the spinal cord
and brain (Di Marzo et al. 2000; Egertová et al. 1998; Felder et al. 1996; Stella et al. 1997).
Supraspinal mechanisms of action for cannabinoids have been demonstrated by studies
which show antinociception in rodent models of acute and chronic pain following administration
of CB1 receptor ligands via intracerebroventricular (i.c.v.) injection, intrathecal (i.t.) injection or
microinjection into specific brain regions. ∆9-THC and synthetic CB1 receptor agonists
WIN55,212-2 and CP55,940 (i.c.v.) produce thermal antinociception in the tail-flick test at doses
that do not significantly alter motor activity, indicating that increased tail-withdrawal latencies
were not the result of motor impairment (Martin et al. 1993; Raffa et al. 1999). Antinociception
in the tail-flick test is also produced following microinjection of CB1 agonists into the amygdala,
thalamus, rostral ventromedial medulla (RVM), and PAG (Lichtman et al. 1996; Martin et al.
1998, 1999). The CB1 receptor antagonist/inverse agonist rimonabant (i.c.v. or i.p.) blocks the
antinociceptive effects of ∆9-THC and CP55,940 (i.c.v. or i.t.), thus demonstrating a CB1dependent mechanism of action (Welch et al. 1998). Additionally, cannabinoids produce
antinociception through interactions with the endogenous opioid system (Fang et al. 2012;
Welch et al.1994, 1995). Alterations in the endocannabinoid system occur in certain brain
regions following nerve injury in models of neuropathic pain. For example, AEA and 2-AG
levels are increased following sciatic nerve injury in the chronic constriction injury (CCI) model
of neuropathic pain in the PAG and RVM (Petrosino et al. 2007). Formalin-evoked pain
behaviors are depressed in rats after partial sciatic nerve ligation (pSNL) and this effect is

blocked by administration of rimonabant into the nucleus reticularis gigantocellularis, a region
involved in descending pain modulation (Monhemius et al. 2001). Lastly, upregulation of
thalamic CB1 receptor mRNA in pSNL rats suggests that increased CB1 receptor density in
certain brain regions may serve to increase the analgesic effects of endocannabinoids during
neuropathic pain states (Siegling et al. 2001).
Both in vivo and in vitro measures have been used to demonstrate spinal mechanisms of
action for the antinociceptive effects of cannabinoids. Levonantradol (i.t.) produces increases in
response latencies of rats in both hot-plate and tail-flick tests (Yaksh, 1981). ∆9-THC (i.t.)
produces thermal antinociception in the tail-flick test in mice following spinal cord transection at
T12, which indicates the antinociceptive effects are not due solely to supraspinal mechanisms
(Smith et al. 1992). Topical application of WIN55,212-2 to the dorsal aspect of the spinal cord
reduces heat-evoked activity in isolated neurons of the hind paw of rats (Hohmann et al. 1998).
CP55,940 (i.t.) attenuates capsaicin-induced sensitization of spinal nociceptive neurons (Johanek
et al. 2005). In the chronic constriction injury (CCI) model of neuropathic pain, spinal AEA and
2-AG levels are elevated and Inhibition of FAAH or MAGL has been shown to reduce
mechanical hypersensitivity (Ignatowska-Jankowska et al. 2015; Kinsey et al. 2009; Petrosino et
al. 2007; Starowicz et al. 2012).
The peripheral antinociceptive effects of cannabinoids involve both CB1- and CB2dependent mechanisms. CB1 receptors undergo peripheral axon flow in DRG neurons and are
expressed on peripheral terminals of nociceptors (Agarwal et al. 2007; Hohmann & Herkenham
1999b). Direct administration of AEA into the hind paw of rats reduces formalin-evoked
nociceptive behavior (Calignano et al. 1998). Local administration of WIN55,212-2 into the
ipsilateral hind paw reduces mechanical hypersensitivity in pSNL rats (Fox et al. 2001). The

CB2-selective agonist AM1241 (local or i.p.) produces thermal analgesia in rats and this effect is
blocked by the CB2-selective antagonist AM630 but not AM251, a CB1-selective antagonist
(Malan et al. 2001). Moreover, AM1241 injected locally to the contralateral hind paw does not
produce thermal antinociception in the ipsilateral paw and AM630 injected locally to the
ipsilateral paw blocks the antinociceptive effects of AM1241 administered systemically (i.p.).
These findings strongly implicate CB2 receptors as the peripheral site of action of cannabinoids.

Chronic Constriction Injury Model of Neuropathic Pain
Neuropathic pain can be modeled through spinal nerve ligation (SNL), partial sciatic
nerve ligation (pSNL), and the chronic constriction injury (CCI) (Bennett & Xie, 1988; Kim &
Chung, 1992; Seltzer et al. 1990). This thesis employees the CCI model of neuropathic pain,
which involves the tying of loose ligatures around the sciatic nerve which results in mechanical
and thermal hypersensitivity in the hind paw either unilaterally or bilaterally, depending on the
technique (De Vry et al. 2004). This model has been used to study the antinociceptive effects of
CB1 and CB2 receptor agonists, allosteric modulators, and inhibitors of biosynthetic or catabolic
enzymes of the endocannabinoids (Donvito et al. 2018).

Investigating the Properties of Cannabinoids in vitro & in vivo

Binding and Functional Assays In Vitro
The binding properties of novel cannabinoid receptor ligands are determined through
binding assays measuring the displacement of a tritium labeled CB1/CB1 agonist such as [3H]CP55,940 (Howlett et al. 2002). The [35S] GTPγS binding assay can be used to measure agonist-

stimulated G protein activation as well as visualize receptor binding in autoradiography
experiments (Howlett et al. 2002; Sim et al. 1995). Inhibition of adenylyl cyclase activity can be
measured through changes in cAMP concentration inside model cells transfected with CB1 or
CB2 receptors (Howlett et al. 1985; Pertwee, 1997). There also exist other functional assays to
measure ß-arrestin recruitment and ERK phosphorylation (Osmond et al. 2005; Zhao et al.
2008).

Behavioral Paradigms for Cannabimimetic Activity
Early studies on cannabinoids involved measuring overt behaviors such as static ataxia in
dogs or ptosis and sedation in monkeys (Walton et al 1937; Edery et al. 1971). More commonly
used models at present include the tetrad assay and drug discrimination paradigm. The tetrad
assay is a measure of cannabimimetic activity wherein direct CB1 agonists produce a full subset
of effects including hypomotility, catalepsy, thermal antinociception, and hypothermia which
strongly correlates with psychoactivity in humans (Martin et al. 1991). The drug discrimination
paradigm is used to measure the subjective effects of CB1 receptor agonists and has been used
extensively to characterize cannabinoid receptor ligands in rodents and non-human primates
(reviewed in Chapter 2). Both the tetrad assay and drug discrimination paradigm have been
useful in drawing structure-activity relationships between cannabinoid receptor ligands and
assessing abuse liability.

Overview of 2-phenyl indoles Represented by ZCZ011
The class of CB1 PAMs represented by ZCZ011 are all characterized by their 2-phenyl
indole backbone (Fig. 1.2). ZCZ011 represents a racemic mixture of its (R)-isomer (ZCZ011A)

and (S)-isomer (ZCZ011B). Other racemates include GAT211, ABD1236 and ABD1236.
Compounds such as LDK1747 and LDK1752 possess a trisubstituted amine which by inversion
renders them achiral. Additions or substitutions at the chiral center or on the indole ring
distinguish each analog and produce varying degrees of change in their activity in vitro or in vivo
summarized in Table 1.1 and 1.2, respectively.

Figure 1.2 Structures of ZCZ011, its structural isomers and analogs.

Pharmacological Effects In Vitro
Table 1.1 Summary of in vitro activity for ZCZ011 analogs and CP55,940
Compound

ZCZ011

Equilibrium

[35S] GTPγS

Binding

Binding

enhances binding:
[3H]-CP55,940 &
[3H]- WIN55,2122

References
cAMP

ß-arrestin

Inhibition

Recruitment

EC50

Emax

EC50

Emax

(nM)

(%)

(nM)

(%)

enhances
binding (AEA)

32

94

777

55

IgnatowskaJankowska et al.
2015; Dai Lu

29

84

828

25

Tseng et al. 2019;
Dai Lu

decreases binding:
[3H]-SR141617A

ABD1236

enhances [3H]CP55,940 binding

-

GAT211

enhances [3H]CP55,940 binding

-

-

129.54

Laprairie et al.
2017; Data
courtesy of Dai
Lu, PhD.

LDK1729

-

-

55

74

>3000

2.1

LDK1730

-

-

47.2

101.5

>10000

12.5

LDK1747

-

-

114.6

92.6

1146

31.1

LDK1752

-

-

20

105

226

57.8

0.14

98.9

1.7

99.7

CP55,940

Data courtesy of
Dai Lu, PhD1.

(-) indicates not reported
(1) personal communication

Pharmacological Effects In Vivo

Table 1.2 Summary of in vivo activity for ZCZ011
Compound

CCI Model of

Tetradb

Neuropathic Paina
ZCZ011

full reversal

Triadc

Drug Discriminationd

[CP55,940]
no

potentiation

no substitution or rate

effect

(3/3)

suppression

potentiates DLR%

Chapter 2: Cannabinoid Drug Discrimination - From Agonism to
Allosteric Modulation
Historical Origins
A more detailed account on the origins of drug discrimination has been written by Donald
Overton; this section provides a briefer summary of his work (Overton, 1991). Drug
discrimination developed from studies on state dependent memory, or state dependent learning
(SDL). SDL is the phenomenon where memory recall performance is dependent on the state of
consciousness or overall physiological state at the time of acquisition and time of recall. When a
behavioral response in an animal is learned under either condition of drug (D) or no drug (N), the
animal performs the behavior most efficiently when the drug condition at the time of training is
reestablished (Overton, 1984). SDL is related to context dependent learning although the key
difference is that context in SDL is the cognitive state of the individual in terms of organic mood
states or synthetic mood states as induced by drugs (Bower, 1981; Grant et al., 1998; Overton
1964). Whereas context dependent learning involves exteroceptive cues (i.e., the environment),
SDL involves interoceptive cues (i.e., cognitive state of the organism). The first case report of
the effects of drugs on memory retrieval came from George Combe who remarked on a story of a
man who when sober could not recall where he had placed a package but upon becoming
intoxicated again was able to relocate the lost item. “The only conclusion which seems to arise
… is that before memory can exist, the organs [have] to be affected in the same manner, or to be
in a state analogous to that in which they were, when the impression was first received” (Combe,
1835). Combe’s report appeared throughout medical literature in the decades following and the
idea that a drug state (e.g., alcohol intoxication) could produce SDL was generally accepted
(Elliotson, 1840; Macnish 1834, 1835; Overton, 1991; Winslow, 1860). In the later part of the

century French physiologist Théodule-Armand Ribot refined this idea by proposing that bodily
“organic sensations”, or interoceptive stimuli, play an important role in memory retrieval (Ribot,
1882, 1891). Investigations involving SDL in the 19th and early 20th centuries helped lay the
conceptual groundwork for the study of drug discrimination. After 1950, advances in the field
and procedural changes marked a transition to the use of what are now considered modern drug
discrimination procedures (Overton 1971, 1982, 1991; Schuster and Balster 1977).
One of the earliest drug discrimination studies involved an approach/avoidance task in
which rats learned to approach an object while intoxicated or avoid while sober, and vice versa
(Conger, 1951). Conger noted that the change in avoidance behavior may have been due solely
to the change in the animals’ internal state (intoxicated vs. sober) rather than to any intrinsic
effects of alcohol intoxication. To demonstrate that drugs can serve as discriminative stimuli,
subsequent studies employed a 2X2 experimental design in which subjects are trained and tested
for recall in groups representing all possible transitions: D (drug) →D, D→N (no drug), N→N,
and N→D (Auld, 1951; Grossman and Miller, 1961; Miller, 1957; Miller and Barry, 1960;
Murphy and Miller, 1955). The 2X2 experimental design proved useful for detecting drug
stimulus effects as it takes into account each possible change of state of the subject though it was
not without limitations. The 2X2 design assumes that SDL is symmetrical in that D→N and
N→D state changes should produce equally large deficits and it cannot distinguish memory
impairment from depressant effects of a drug on performance. An improvement to drug
discrimination methodology came with the incorporation of symmetrical tasks such as the twochoice T-maze. In using a symmetrical drug discrimination task, drug stimulus properties are
measured according to response selection rather than response occurrence (Overton 1961, 1964).

In 1968, Harris and Balster applied operant conditioning to the drug discrimination
paradigm whereby they trained rats to discriminate DL-amphetamine from saline on two-lever
(TL) multiple fixed ratio 50/differential-reinforcement-of-low-rate 20s (MULT FR50, DRL 20s).
They showed that the rats acquired the amphetamine discriminative cue and demonstrated
condition-appropriate responding under extinction conditions (Harris & Balster, 1968). Studies
employing the operant drug discrimination paradigm generated ED50 values for dose-response
curves much lower than reported in T-maze paradigms (Kubena & Barry, 1969a, b; Morrison &
Stephenson 1969). A major step that helped standardize the two-lever drug discrimination
procedure was the introduction of fixed ratio (FR) schedules of reinforcement where a pellet
reward is given, for example, every tenth condition-appropriate response (FR10). A study in
1975, in which rats trained to discriminate fentanyl using a TL FR10 schedule of reinforcement,
showed that the discriminative stimulus effects of fentanyl were dose-dependent and
pharmacologically specific (i.e., generalized only to drugs of the same class) and measurement of
response rates could detect inhibitory or stimulatory effects of a drug (Colpaert & Niemegeers,
1975).
The standard approaches and utility of two-lever operant drug discrimination procedures
were apparent by the mid-1970s. In 1976, Shannon and Holtzman trained rats to discriminate
morphine (3.0 mg/kg) from saline in a shock avoidance procedure. They demonstrated that the
discriminative stimulus effects of morphine were time and dose-dependent, pharmacologically
specific, stereoselective, and cross-tolerant with the discriminative cue of methadone (Shannon
& Holtzman, 1976). These characteristic features of receptor-mediated pharmacology have also
been demonstrated with other classes of drugs aside from opioids, highlighting the utility of
discrimination paradigms for the classification of drugs according to their discriminative

stimulus effects. Major drug classes which produce a discriminative stimulus include stimulants,
depressants, opioids, hallucinogens, dissociative anesthetics, and cannabinoids. Drug
discrimination became increasingly popular among behavioral pharmacologists as a tool to
investigate drugs of abuse. Table 1 gives a partial list of drugs that have been used as a
discriminative stimulus in drug discrimination paradigms. From the body of literature on drug
discrimination arise a few core principles. The first is that the discriminative stimulus properties
of a drug are generally considered to be reflective of its subjective effects. For example, a drug
that substitutes for the discriminative stimulus of ∆9-THC in rodents is likely to produce the
same subjective ‘high’ feeling in humans as ∆9-THC. Sensitivity to discriminative stimuli may
also vary between individuals in human and nonhuman subjects. Second, that drugs may be
classified according to their discriminative stimulus properties and this feature may be used to
study tolerance and cross-tolerance among drugs of the same class. Lastly, that the
discriminative stimulus properties of a drug are stereospecific, and their action reflects CNS
activity at specific neurotransmitter receptors.

Table 2.1

Partial list of drugs exhibiting discriminative stimulus properties†

Drug

Class or Receptor Mechanism

Reference

amphetamine

stimulant

Schechter and Rosecrans,
1973

apomorphine

dopamine receptor agonist

Colpaert et al., 1975

atropine

antimuscarinic

Barry and Kubena, 1972

buprenorphine

opioid analgesic, MOR partial

Holtzman, 1997

agonist

buspirone

anxiolytic

Hendry et al., 1983

caffeine

stimulant

Carney and Christensen,
1980

cholecystokinin

neuropeptide hormone

De Witte et al., 1985

chlorpromazine

antipsychotic

Goas and Boston, 1978

clozapine

antipsychotic

Browne and Koe, 1982

cocaine

stimulant

Järbe, 1978

desipramine

antidepressant

Shearman et al., 1978

dextromethorphan

antitussive

Holtzman, 1994

diazepam

anxiolytic

Young et al., 1986

diphenhydramine

antihistamine

Winter, 1985

DOM

hallucinogen

Young et al., 1980

ephedrine

sympathomimetic

Young and Glennon, 1998

ethanol

sedative

Schechter, 1974

fenfluramine

anorectic

Goudie, 1977

fentanyl

opioid analgesic, MOR partial

Colpaert et al., 1975

agonist
imipramine

tricyclic antidepressant

Zhang and Barret, 1991

LSD-25

hallucinogen

Hirschhorn and Winter, 1971

MDA

empathogen-entactogen

Glennon and Young, 1984

MDMA

empathogen-entactogen

Glennon and Misenheimer,
1989

morphine

opioid analgesic, MOR agonist

Hirschhorn and Rosecrans,
1974

naloxone

MOR antagonist

Carter and Leander,1982

nicotine

nAChR agonist

Schechter and Rosecrans,
1972

NMDA

NMDAR agonist

Willetts and Balster, 1989

pentazocine

opioid analgesic, MOR agonist

Kuhn et al., 1976

pentobarbital

sedative

Herling et al., 1980

phencyclidine

dissociative anesthetic

Brady and Balster, 1981

pregnenolone

neurosteroid hormone

Vanover, 1997

∆9-THC

CB1 receptor agonist

Järbe et al., 1977

Toluene

abused inhalant

Rees et al., 1987

MOR µ-opioid receptor, LSD lysergic acid diethylamide, MDA 3, 4methylenedioxyamphetamine, MDMA 3, 4-methylenedioxymethamphetamine, nAChR nicotinic
acetylcholine receptor, CB1 cannabinoid receptor subtype-1, ∆9-THC delta-9tetrahydrocannabinol
† Source: Richard Young in chapter 3 of Methods of Behavior Analysis in Neuroscience, 2nd
edition
The first behavioral pharmacologists investigating in vivo effects of cannabinoids
employed drug discrimination procedures developed in the 1960s and 1970s. Cannabinol (CBN)
was the first structurally confirmed phytocannabinoid isolated from cannabis. Early
pharmacological studies showed that tetrahydrocannabinols, compared to other compounds such
as cannabidiol (CBD) are the primary psychoactive constituents of cannabis (Cahn, 1933; Loewe
1946). It was not until the 1960s however that advances in separation techniques and structural
determination led to the isolated structures of ∆9-THC and CBD (Gaoni & Mechoulam, 1964;
Mechoulam & Shvo, 1963). By the 1970s the techniques for isolation, structural confirmation,

and synthesis of major and other phytocannabinoids were well established (Mechoulam &
Gaoni, 1965, 1967, 1971). Research around the time focused primarily on developing bioassays
to quantify the behavioral effects of cannabis and its individual cannabinoid constituents,
establishing pharmacokinetic pathways for those compounds, and constructing structure-activity
relationships (Agurell, 1986; Edery et al., 1971; Pertwee, 1972). The first animal model used to
study the effects of cannabinoids was measuring static ataxia in dogs which consists of sedation,
catalepsy, motor impairment, and hyperexcitability (Walton, 1937). Another useful model was
studying overt behaviors in monkeys (e.g., sedation, ptosis, slouched posture, hyperexcitability).
Static ataxia and overt behavior models were reliable for assessing structure activity relationships
for cannabinoids and novel structural analogs, demonstrating both stereospecificity, shifts in
potency, and high correlation with psychoactivity (Edery et al., 1971; Martin et al., 1975).
Concurrent with the advances in cannabinoid pharmacology following the discoveries of
Mechoulam, was the development of drug discrimination procedures. By the time ∆9-THC had
been isolated and synthesized, operant drug discrimination tasks had already proven useful for
characterizing the discriminative stimulus effects of drugs of abuse such as amphetamine or
alcohol (Harris & Balster, 1968; Kubena & Barry, 1969a, b; Morrison & Stephenson, 1969).
Cannabinoid researchers now had a reliable tool for measuring the subjective effects of
cannabinoids in addition to predicting psychoactivity whereas previous behavioral measures
were strictly models of intoxication.
In 1971, ∆9-THC was shown to produce SDL in rats under a conditioned avoidance
paradigm, suggesting that it might also serve as a discriminative stimulus as had been
demonstrated with other drugs known to produce SDL (Henriksson & Järbe, 1971). ∆9-THC was
used as a discriminative stimulus the following year in a study, which trained male Wistar rats in

an operant-lever shock avoidance procedure to discriminate the effects of ∆9-THC from vehicle
and a variety of other pharmacological agents (Kubena & Barry, 1972). It was successfully
demonstrated that ∆9-THC produces a discriminative cue that does not generalize to drugs of
other classes or to non-psychoactive cannabinoids such as CBD. That same year Henriksson &
Järbe successfully trained Sprague-Dawley rats to use ∆9-THC as a discriminative stimulus in a
water T-maze position learning task (Henriksson & Järbe, 1972). Järbe and collaborators
published much of the early literature on cannabinoid drug discrimination in the following years
(Järbe & Henriksson, 1974; Järbe et al. 1975, 1977; Järbe & McMillan 1979, 1980). These
studies corroborated evidence from other behavioral models showing ∆9-THC is the primary
psychoactive component of cannabis in addition to novel generalization tests. Important structure
activity relationships were also demonstrated, with analogs of ∆9-THC (e.g., ∆8-THC) or its 11hydroxy metabolites generalizing to the discriminative cue of ∆9-THC. Lastly, these studies
showed that other species including gerbils and pigeons learn to discriminate ∆9-THC from
vehicle and other compounds (Table 2.2). The work on cannabinoid drug discrimination strongly
suggested a common mechanism of action for these drugs. However, the mechanism of action
mediating the pharmacological effects of cannabinoids remained under debate until the
development of a cannabinoid receptor radioligand binding assay and the cloning of cannabinoid
receptors from rat brain and later from human brain (Devane et al. 1998; Matsuda et al. 1990;
Munro et al. 1993).
Drug discrimination remained a useful and reliable tool in the cannabinoid field
following the discovery of cannabinoid receptors. The model was extended to Rhesus monkeys
which was used to characterize novel cannabinoids such as CP55,940 and WIN55,212-2 with the
intention of providing a more accurate correlate of psychoactivity in humans than the rodent and

avian drug discrimination studies (Gold et al. 1992; Compton et al. 1992). The discriminative
stimulus effects of the endogenous cannabinoid AEA and/or its metabolically stable analogs
were characterized following their discovery, effectively showing that CB1 receptors mediate
their discriminative stimulus effects (Wiley et al. 1995a; Burkey and Nation, 1997). The
discriminative stimulus effects of the other endocannabinoid 2-AG were characterized indirectly
by using inhibitors of its degradative enzyme, MAGL (Wiley et al. 1995b, c; Solinas et al. 2007;
Walentiny et al. 2011). Hence the role of the endocannabinoid system in cannabinoid drug
discrimination can be studied through administration of CB1 receptor agonists or indirectly by
pharmacological blockade of endocannabinoid degradation. Whether by administration of
exogenous agonist or pharmacologic blockade of MAGL and/or FAAH, the common feature
among all previously mentioned studies is that they quantify discriminative stimulus effects in
terms of CB1 agonism and antagonism, through generalization and antagonism tests. More
recently however, CB1 receptor allosteric modulators have been investigated in the drug
discrimination paradigm, CB1 receptor allosteric modulators which do not substitute for CB1
receptor orthosteric agonist training drugs but can produce shifts in the dose-response curves of
the generalization curves of the training drugs (Gamage et al. 2014; Ignatowska-Jankowska et al.
2015). Published reports investigating CB1 receptor allosteric modulators suggest potential
therapeutic applications and advantages over direct agonism or antagonism making CB1 receptor
allosteric modulation an exciting area for drug development to which the drug discrimination
paradigm lends itself well. ZCZ011 for example is a CB1 positive allosteric modulator (PAM),
which reverses allodynia in a mouse chronic constriction injury (CCI) model of neuropathic pain
but lacks intrinsic cannabimimetic activity similar to ∆9-THC (Ignatowska-Jankwoska et al.
2015). Moving forward, cannabinoid drug discrimination offers a reliable in vivo model to screen

novel CB1 receptor allosteric modulators and their structural analogs. The remainder of this
review will cover important concepts in drug discrimination, both theoretical and methodological
as well as discuss separately the discriminative stimulus effects of phytocannabinoids,
endogenous cannabinoids, cannabinoid antagonists, and cannabinoid allosteric modulators. Table
2 provides a summary of substitution profiles for cannabinoid and non-cannabinoid drugs
discussed in this review.
Table 2.2 Substitution profiles of various drugs under cannabinoid discrimination procedures
Training drug,
dose (mg/kg),
routea

Test drug,
dose (mg/kg),
routea

Species

Procedureb

Result,
%DLRc

Response
ratesd

References

Non-cannabinoid drugs of abuse
∆9-THC, 3.0

amphetamine,

Male, SD

Solinas et al.
TL, FR10

0.3-1.8

rats

amphetamine,

Male, SD

0.32

rats

N.S.

decrease
(2010)

TL, FR10,

∆9-THC, 3.2

∆9-THC, 5.0

CS-

amphetamine,

Male, SD

2.5-5.0

rats

Browne and
N.S.

no effect

reinforced

(1981)

water T-

Järbe and

maze, escape

N.S.

n/a

reinforced

∆9-THC, 3.0

Solinas et al.
TL, FR10

N.S.

decrease

rats

(2010)
water T-

∆9-THC, 5.0

Henriksson
(1974)

Male, SD
cocaine, 1-10

Weissman

Järbe and

Male, SD
cocaine, 5-20

maze, escape

N.S.

n/a

Henriksson

rats
reinforced

(1974)

∆9-THC, 10

Male,

TH, FR30,

C57BL6/

CM-

J mice

reinforced

McMahon et
cocaine, 10-56

N.S.

decrease
al. (2008)

∆9-THC, 0.04-

diazepam, 0.025-

Rhesus

P.S.
TL, FR50

0.17 IM

1.2

monkeys

Wiley et al.
no effect

31

(1995b)

TL, FR10,

∆9-THC, 3.0

Male, SD
diazepam, 0.1-10

P.S.
SM-

rats

Mokler et al.
decrease

64

(1986)

reinforced
water T-

∆9-THC, 5.0

ethanol, 1000-

Male, SD

2000

rats

maze, escape

Järbe and
N.S.

n/a

reinforced

∆9-THC, 1.8

Male, SD
ethanol, 300-1000

∆9-THC, 10

(1974)
P.S.

TL, FR10
rats

Järbe et al.
decrease

48

Male,

TH, FR30,

C57BL6/

CM-

J mice

reinforced

Male,

TH, FR30,

C57BL6/

CM-

J mice

reinforced

(2010)

P.S.
ethanol, 320-1000

McMahon et
decrease

25

∆9-THC, 10

al. (2008)

P.S.
ketamine, 3.2-32

McMahon et
decrease

34

al. (2008)

TL, FR10,

∆9-THC, 3.2

Henriksson

Browne and

Male, SD
LSD, 0.1

CS-

N.S.

decrease

Weissman

rats

∆9-THC 5.0 or

morphine, 1.25-

Male, SD

hashish smoke

10

rats

reinforced

(1981)

water T-

Järbe and

maze, escape

n/a

reinforced

∆9-THC, 0.04-

Wiley et al.
TL, FR50

monkeys

Henriksson
(1974)

Rhesus
morphine, 0.1-1.0

0.17 IM

N.S.

N.S.

no effect
(1995b)

TL, FR10.

∆9-THC, 3.2

Male, SD
morphine, 3.2

Browne and
P.S.

CSrats

no effect

reinforced

∆9-THC, 0.04-

phencyclidine
0.03-0.3

(1981)

Rhesus

Wiley et al.
TL, FR50

0.17 IM

Weissman

20

N.S.

no effect

monkeys

(1995b)

Phytocannabinoids and Endogenous Cannabinoids
∆9-THC, 3.0

Male, SD
anandamide, 45

Wiley et al.
TL, FR10

F.S.

decrease

rats

∆9-THC, 0.08-

anandamide, 0.1-

Rhesus

(1995a)
TL, FR50-

Wiley et al.
inconsistent

0.16 IM

10

monkeys

100

anandamide, 0.5-

Male, SD

TL, FR10,

P.S.

16

rats

SW

37.7

no effect
(1997)
Burkey and

∆9-THC, 2.0

decrease

Nation
(1997)

∆9-THC, 1.8-

anandamide, 10-

Male, SD

Järbe et al.
TL, FR10

5.6

∆9-THC, 30

18

N.S.

decrease

rats

(2001)

Male,

TH, FR10,

C57BL6/

SM-

J mice

reinforced

anandamide, 3.0-

Wiley et al.
N.S.

no effect

100

methanandamid

anandamide, 10-

(2011)

Male, SD

Järbe et al.
TL, FR10

e, 10

18

rats

cannabidiol, 10-

Male, SD

32

rats

F.S.

decrease
(2001)

TL, FR10,

∆9-THC, 3.2

∆9-THC, 3.2

Browne and
P.S.

CS-

no effect

Weissman

25
reinforced

(1981)

TL, FR10,

Browne and

Male, SD
cannabinol, 6.77

CS-

F.S.

no effect

Weissman

rats
reinforced

(1981)

water T-

∆9-THC 5.0 or
hashish smoke

hashish smoke

∆9-THC, 12-16

Järbe and

Male, SD
maze, escape

F.S.

n/a

Henriksson

rats
reinforced
Male,

T-maze,

Mongolia

escape-

n gerbils

reinforced

(1974)
Järbe et al.

hashish smoke

F.S.

n/a
(1975)

mixed

amphetamine,

∆9-THC, 0.125-

1.6 IM

0.5 IM

strain,

TK, FR15

N.S.

decrease

Järbe (1982)

TK, FR15

N.S.

decrease

Järbe (1984)

TL, FR10

F.S.

decrease

pigeons
white

cocaine, 3.0 IM

∆9-THC, 0.3 IM

Carneau
pigeons

methanandamid

Male, SD
∆9-THC, 0.1-3.0

e, 10

rats

∆9-THC, 0.2 IM

0.20 IM

Henriksson
strain,

TK, FR15

F.S.

decrease
et al. (1975)

pigeons
Male,

∆9-THC, 5.6
∆9-THC, 5.6

s.c.

C57BL6/

TH, FR10

not

Long et al.

reported

(2009)

not

Long et al.

reported

(2009)

F.S.

J mice
Male,

∆9-THC, 5.6
∆9-THC, 5.6

s.c.

FAAH (-/-)

TH, FR10

F.S.

mice
Male,
anandamide, 1.0-

Walentiny et
FAAH (-/-)

s.c.

(2001)

mixed

∆9-THC, 0.15-

∆9-THC, 5.6

Järbe et al.

30 s.c.

TH, FR10

F.S.

decrease
al. (2015)

mice

11-OH-∆9-THC,

∆9-THC, 3.0

Järbe and
Male, SD

11-OH-∆8,

0.3-

TL, FR10

F.S.

decrease

McMillan

rats
3.0

(1980)

11-OH-∆9-THC

Male,

0.03-1.0, 11-OH-

white

∆8-THC 0.1-1.0

Carneau

IM

pigeons

Järbe and

∆9-THC, 1.0

TK, FR15

F.S.

decrease

McMillan
(1980)

pentobarbital,

Male,

T-maze,

Mongolia

escape-

n gerbils

reinforced

Järbe et al.
∆9-THC, 2.0-8.0

20

N.S.

n/a
(1975)

Selective and Dual FAAH/MAGL Inhibitors
anandamide, 0.3-

∆9-THC, 3.0

Male, SD
3.0 i.v. +

Solinas et al.
TL, FR10

F.S.

decease

rats

(2007)

URB597, 0.3
Male,

∆9-THC, 5.6

P.S.
JZL184, 40

s.c.

not

Long et al.

reported

(2009)

not

Long et al.

reported

(2009)

not

Long et al.

reported

(2009)

not

Long et al.

reported

(2009)

TH, FR10
50

J mice
Male,

∆9-THC, 5.6
JZL195, 40

s.c.

C57BL6/

TH, FR10

F.S.

J mice
Male,

∆9-THC, 5.6
JZL184, 40

s.c.

FAAH (-/-)

TH, FR10

F.S.

mice
Male,

∆9-THC, 5.6
JZL195, 40

s.c.

C57BL6/

FAAH (-/-)
mice

TH, FR10

F.S.

Male,

∆9-THC, 5.6
KML29, 40 s.c.

s.c.
∆9-THC, 5.6
KML29, 40 s.c.

s.c.

∆9-THC, 5.6

C57BL6/

IgnatowskaTH, FR10

N.S.

et al. (2014)

Male,

Ignatowska-

FAAH (-/-)

TH, FR10

F.S.

∆9-THC, 5.6

JZL195, 120

Male,

TH, FR10,

C57BL6/

SM-

J mice

reinforced

Male,

TH, FR10,

C57BL6/

SM-

J mice

reinforced

Male,

TH, FR10,

C57BL6/

SM-

J mice

reinforced

s.c.

2.5 s.c.

C57BL6/

CP55,940, 0.1,
JZL184, 4.0-100

s.c.

reported

(2015)

not

Hruba et al.

reported

(2015)

not

Hruba et al.

reported

(2015)

F.S.

F.S.

IgnatowskaTH, FR10

F.S.

increase

Jankowska
et al. (2015)

Male,

Ignatowska-

C57BL6/

TH, FR10

F.S.

no effect

J mice

Jankowska
et al. (2015)

Male,
JZL184, 1.0-40

P.S.
TH, FR10

s.c.

Walentiny et
no effect

50

al. (2015)

J mice
Male,

∆9-THC, 5.6

Walentiny et
JZL195, 40 s.c.

s.c.

Hruba et al.

J mice

C57BL6/

s.c.

not
F.S.

Male,
MJN110, 0.25-

Jankowska
et al. (2014)

JZL184, 120 +

CP55,940, 0.1,

∆9-THC, 5.6

no effect

mice

SA-57, 10

Jankowska

J mice

PF3845, 10

∆9-THC, 5.6

no effect

C57BL6/

TH, FR10

F.S.

no effect
al. (2015)

J mice

∆9-THC, 5.6

Male,
JZL184, 1.0-40

Walentiny et
FAAH(-/-)

s.c.

TH, FR10

F.S.

no effect

s.c.

al. (2015)
mice
Male,

∆9-THC, 5.6

P.S.
JZL195, 40 s.c.

s.c.

FAAH(-/-)

TH, FR10

Walentiny et
no effect

74

al. (2015)

mice

Synthetic Cannabinoids
Burkey and

∆9-THC, 2.0

CP55,940, 0,05-

Male, SD

TL, FR10,

0.8

rats

SW

F.S.

decrease

Nation
(1997)

∆9-THC, 30

Male,

TH, FR10,

C57BL/6

SM-

J mice

reinforced

methanandamide,

Male, SD

TL, FR10,

0.5-8.0

rats

SW

CP55,940, 0.01-

Wiley et al.
F.S.

decrease

3.0

(2011)
Burkey and

∆9-THC, 2.0

F.S.

decrease

Nation
(1997)

∆9-THC, 3.0

methanandamide,

Järbe et al.
TL, FR10

10-18

∆9-THC, 30

Male, SD
F.S.

decrease

rats

(2001)

Male,

TH, FR10,

C57BL/6

SM-

J mice

reinforced

methanandamide,

Wiley et al.
N.S.

decrease

30-100

∆9-THC, 3.0

∆9-THC, 3.0

rimonabant, 0.3-

(2011)
Male, SD

Wiley et al.
TL, FR10

5.6

rats

WIN55,212-2,

Male, SD
rats

no effect
(1995c)
Wiley et al.

TL, FR10
0.1-3.0

N.S.

F.S.

decrease
(1995c)

JWH018

∆9-THC, 3.0

Gatch and
Male, SD

(AM678), 0.03-

TL, FR10

F.S.

no effect

Forster

rats
1.0

(2014)

JWH018

∆9-THC, 1.8

Male, SD
(AM678), 0.03-

Järbe et al.
TL, FR10

F.S.

no effect

rats

(2010)

1.0
Gatch and

∆9-THC, 3.0

Male, SD
JWH073, 0.1-10

TL, FR10

F.S.

decrease

Forster

rats
(2014)
Gatch and

∆9-THC, 3.0

Male, SD
JWH200, 0.1-10

TL, FR10

F.S.

no effect

Forster

rats
(2014)

∆9-THC, 10 s.c.

Male,

TL, FR10,

C57BL6/

SM-

J mice

reinforced

Male,

TL, FR10,

C57BL6/

SM-

J mice

reinforced

Male,

TL, FR10,

C57BL6/

SM-

J mice

reinforced

JWH-202, 1.0-30

Vann et al.
N.S.

no effect

s.c.

∆9-THC, 10 s.c.

(2009)

JWH-204, 0.3-10

Vann et al.
F.S.

no effect

s.c.

∆9-THC, 10 s.c.

(2009)

JWH-205, 1.0-56

Vann et al.
F.S.

decrease

s.c.

(2009)
Gatch and

∆9-THC, 3.0

AM2201, 0.03-

Male, SD

1.0

rats

TL, FR10

F.S.

no effect

Forster
(2014)
Järbe and

∆9-THC, 3.0

Male, SD
SP111 1.0-10

TL, FR10

F.S.

decrease

McMillan

rats
(1980)

Male,
Järbe and

∆9-THC, 1.0

white
SP111 1.0-10

TK, FR15

F.S.

decrease

McMillan

Carneau
(1980)
pigeons
Male,

∆9-THC, 5.6

Wiley et al.
UR-144, 0.3-10

C57BL6/

TL, FR10

F.S.

decrease
(2013)

J mice
Male,

∆9-THC, 5.6

Wiley et al.
XLR-11, 0.3-10

C57BL6/

TL, FR10

F.S.

decrease
(2013)

J mice

∆9-THC, 5.6

Male,
O-1812, 0.03-1.0

Walentiny et
C57BL6/

s.c.

s.c.

methanandamid

methanandamide,

e, 70

F.S.

no effect
al. (2015)

J mice
Male,

TH, FR10,

C57BL6/

SM-

J mice

reinforced

Male,

TH, FR10,

C57BL6/

SM-

J mice

reinforced

Wiley et al.
F.S.

decrease

30-100

methanandamid

(2011)

Wiley et al.
∆9-THC, 3.0-100

e, 70

TH, FR10

N.S.

decrease
(2011)

F.S. full substitution, P.S. partial substitution, N.S. no substitution, IM intramuscular route of
administration, s.c. subcutaneous route of administration, DLR drug lever or drug-like
responding, TL two-lever choice, TH two-hole choice nose-poke, TK two-key choice, SD
Sprague-Dawley rats, FR fixed ratio, CM 1:1 condensed milk and water, CS 1:1 carnation
slender and water, SW dilute (0.4%) saccharin solution, SM sweetened milk
(a) Intraperitoneal route of administration unless otherwise stated
(b) Food-pellet reinforced unless otherwise stated
(c) Full substitution defined as ≥80% DLR; No substitution defined as 20% DLR
(d) Effect on rate of responding with respect to the highest dose tested

Core Concepts and Principles of Drug Discrimination
The studies listed in Table 2 demonstrate important concepts that make drug
discrimination a reliable preclinical tool for studying cannabinoids in vivo. It is evident that drug
discrimination can be used to classify drugs according to their discriminative stimulus properties
and that these effects are mediated through receptor specific neural mechanisms. Morphine for
example which acts via µ-opioid receptors does not substitute for the discriminative stimulus of
∆9-THC in rats or monkeys trained to discriminate ∆9-THC from vehicle (Järbe & Henriksson,
1974; Browne & Weissman, 1981; Wiley et al. 1995d). Overall, drug discrimination is useful for
investigating novel compounds of structurally similar and dissimilar cannabinoids including CB1
receptor agonists, inverse agonists, and allosteric modulators. Drug discrimination also clearly
demonstrates aspects of receptor mediated pharmacology in that the discriminative stimulus
effects of cannabinoids are dose-dependent, stereospecific, antagonizable, and subject to
tolerance with cross-tolerance seen between cannabinoids with similar activity (i.e. CB1 receptor
agonists are cross tolerant with one another). Although these features can be demonstrated with
other bioassays, various aspects of drug discrimination make it an excellent model for drug
development in the cannabinoid field.

Subjective Effects of Drugs
There is a general consensus in the field of drug discrimination that the model provides a
means by which the subjective effects of drugs can be quantified (Colpaert et al. 1976;
Hirschhorn & Rosecrans, 1976; Shannon & Holtzman, 1976). Subjective effects of drugs refer to
the effects which are mediated through a drug’s action on the CNS rather than any peripheral
effects. The subjective effects of morphine for example can be attributed to its agonist action at

µ-opioid receptors in the CNS rather versus peripheral analgesic mechanisms in dorsal root
ganglia (DRG) (Colpaert & Niemegeers, 1975; Colpaert et al. 1975). One should use caution
when interpreting subjective drug effects between animal and human models of drug
discrimination. For humans, oral reports can provide a detailed description of how a drug makes
them feel and how its subjective effects correlate with its discriminative stimulus properties
(Chait et al. 1984, 1985, 1986a, 1986b, 1988). Discrimination studies in humans have also
revealed sex differences in the subjective effects of ∆9-THC in cannabis users (Fogel et al.
2017). The same degree of qualitative information on the subjective effects of drugs cannot be
ascertained from animals; however, the key point is that drug discrimination tasks do not ask the
subjects how they feel but rather quantitatively ascertains the interoceptive effects of a drug.
As a reliable model for measuring subjective drug effects, drug discrimination is also
used as preclinical model for assessing abuse liability of novel cannabinoids. Should a compound
substitute for the discriminative stimulus of a known drug of abuse, that compound is inferred to
have potential liability. Drug self-administration has largely overtaken drug discrimination as a
model for drug abuse in the last twenty years as the neural circuitry involved in drug-reinforced
behavior is more well defined than the mechanisms responsible for discriminative stimulus
effects and that it has high face-validity for drug abuse in humans (reviewed in McMahon,
2015). However, few studies have demonstrated cannabinoid self-administration in nonhuman
animals (Carney et al., 1977; Young et al., 1981; Tanda et al., 2000). Additionally, drug
discrimination compared to other behavioral paradigms is highly sensitive to cannabinoids. ∆9THC is more potent in regard to its subjective effects as measured by drug discrimination than it
is in producing the full tetrad set of cannabimimetic effects consisting of hypomotility, catalepsy,
antinociception, and hypothermia (Long et al. 2009; Marshell et al. 2014). CB1 receptor agonists

may also produce full substitution at doses that do not negatively affect response rates (Vann et
al., 2009) whereby the subjective effects of cannabinoids therefore are detected prior to
alteration of overt behaviors such as locomotion. The subjective effects of drugs (contrary to
their namesake) are an objectively useful quality which investigators analogously quantify as a
discriminative stimulus.

Receptor Mechanisms of Discriminative Stimulus Effects
The CB1 receptor is the most abundant GPCRs in the CNS and is highly expressed
throughout the neocortex, basal ganglia, hippocampus, cerebellum, and brainstem (Herkenham et
al. 1990, 1991; Glass et al. 1997; Tsou et al. 1998). The neuroanatomic distribution of CB1
receptors correlates with its role in the endocannabinoid system and is responsible for mediating
the effects of exogenous agonists such as ∆9-THC or synthetic cannabinoids. Pharmacological
and genetic techniques have been used in conjunction with various behavioral paradigms to parse
out the role of CB1 receptors in different brain regions (Zimmer et al. 1999; Wilson-Poe et al.
2012). CB1 receptors are primarily coupled to pertussis toxin (PTX)-sensitive Gαi/o proteins and
activation by agonists leads to inhibition of adenylyl cyclase as well as modulation of voltagegated calcium channels and potassium channels (Mackie et al. 1995; Twitchell et al. 1997; Guo
& Ikeda, 2004). The net cellular effect of CB1 receptor activation is dependent on the cell-type
on which they are expressed and the cell's dominant neurotransmitter product.
CB1 receptors are primarily localized to presynaptic axon terminals of GABAergic and
glutamatergic neurons where they mediate inhibition of neurotransmitter release (Straiker &
Mackie, 2005). Astrocytes express CB1 receptors to a lesser extent, though understanding how
they play an important role in modulating synaptic transmission and plasticity is increasing (Han

et al. 2012). The endocannabinoids 2-AG and AEA are synthesized on demand from membrane
phospholipids in the postsynaptic membrane and signal in a retrograde fashion (Bisogno et al.
2003; Katona et al. 2006). The discriminative stimulus effects of cannabinoids are produced as a
result of their neuromodulatory capacity. Other sedative drugs which modulate GABAergic
neurotransmission including barbiturates and benzodiazepines may partially substitute for ∆9THC in drug discrimination paradigms but full substitution is only achieved from CB1 receptor
activation (see Table 2).
CB1 receptor agonists both endogenous and synthetic produce a discriminative stimulus
in a dose dependent manner that can be generalized. Differences in structure may impart
differences in potency. 11-OH-∆9-THC and 11-OH-∆8-THC (∆9-THC metabolites) both
generalize to ∆9-THC with the ∆9 isomer being more potent, thereby demonstrating
stereoselectivity (Järbe & McMillan, 1979). Discriminative stimulus effects of cannabinoids are
also stereospecific. The (+) configuration of WIN55,212-2 produces a discriminative stimulus
similar to ∆9-THC whereas (-)-WIN55,212-2 has no effect (Compton et al. 1992). The CB1
receptor inverse agonist rimonabant (SR141617A) dose-dependently antagonizes the
discriminative stimulus effects of CB1 receptor agonists (Wiley et al. 1995c; Pério et al. 1996;
Järbe et al. 2001; Walentiny et al. 2015). Finally, CB1 receptor allosteric modulators may
enhance or diminish the potency of the discriminative stimulus of CB1 receptor agonists. The
positive allosteric modulator (PAM) ZCZ011 for example does not elicit a discriminative
stimulus alone but produces a leftward shift in the dose-response curves of CP55,940 and AEA
(Ignatowska-Jankowska et al. 2015).

Tolerance and Cross-Tolerance
The subjective effects of ∆9-THC and other CB1 receptor agonists are only modestly
affected by tolerance in that full substitution can be seen at doses that do not impair response
rates (Hruba et al. 2012; Vann et al. 2009). This was demonstrated almost 40 years ago in a
study that used trained rats to discriminate ∆9-THC from vehicle and used rope-climbing
performance as a measure of tolerance (Bueno et al. 1972). They found that after daily training
sessions with ∆9-THC, the rats became tolerant to the drugs impairing effects on rope-climbing
but still discriminated ∆9-THC from vehicle, suggesting that its discriminative stimulus
properties were not subject to tolerance. Furthermore, lever response rates remain stable
throughout chronic administration and it has been shown that chronic administration of ∆9-THC
at higher doses than the training dose produces only minor decreases in the degree of differential
responding (Hirschhorn & Rosecrans, 1974). Under standard drug discrimination acquisition
training, subjects do not develop appreciable tolerance to the discriminative stimulus of the
training drug apart from under certain modifications. For example, rats trained to discriminate
3.0 mg/kg ∆9-THC were then administered either vehicle or a high dose of ∆9-THC during a
period of suspended training (Wiley et al. 1993). Rats subjected to the high dose treatment of
∆9-THC showed a 40-fold rightward shift in their dose-response compared to the dose-response
curve generated under the prior training dose regimen. This shift in the potency suggested the
rats developed tolerance to the discriminative stimulus effects of ∆9-THC. This result is
consistent with the effect that higher training dose produces higher ED50 values (Schechter,
1983; Solinas et al. 2006). As such, the discriminative stimulus effects of CB1 receptor agonists
can undergo tolerance but solely through repeated administration of high doses, atypical for drug
discrimination training or testing. The lack of cannabinoid compound tolerance under standard

training doses makes drug discrimination a very reliable model for studying CB1 receptor
pharmacology in vivo.

Drug Discrimination in Drug Development
Drug discrimination has demonstrated pharmacological specificity for a variety of drug
classes including cannabinoids and has been employed by pharmaceutical companies,
government agencies, and academic institutions for the classification of novel compounds.
Olanzapine, an atypical antipsychotic was approved by the FDA four years following a study,
which demonstrated that it fully substituted for the cue in animals trained to discriminate the
atypical antipsychotic clozapine (Moore et al. 1992). The DEA has made use of drug
discrimination for scheduling purposes in assessing abuse liability of illicit drugs such as
substituted cathinones. Drug discrimination studies have also provided the DEA with evidence
for the scheduling of synthetic cannabinoids commonly found on the gray market (Gatch &
Forster 2014, 2015). With respect to cannabinoids, drug discrimination has proven useful in
establishing structure activity relationships of novel cannabinoids both structurally similar and
dissimilar to ∆9-THC such as CP47,497 and those frequently used in research, CP55,940 and
WIN55,212-2 (Grim et al. 2016; Wiley et al. 1995c; Compton et al. 1992). In addition to
exogenous cannabinoid agonists, drug discrimination has also been used in the development of
metabolically stable analogs of the endocannabinoids 2-AG and AEA as well as inhibitors of
their respective catabolic enzymes, MAGL and FAAH (Wiley et al. 1997; Solinas et al. 2007;
Long et al. 2009; Hruba et al. 2015; Walentiny et al. 2015). Most recently drug discrimination
has been used to assess the activity of CB1 receptor allosteric modulators such as ZCZ011,

Org27569, and novel analogs of those compounds (Gamage et al. 2014; Ignatowska-Jankowska
et al. 2015).

Discriminative Stimulus Properties Cannabinoid Agonists
Cannabinoids are derived from three primary sources: species of the genus Cannabis
(phytocannabinoids), organic synthesis in laboratories (synthetic cannabinoids), and endogenous
biosynthesis (endocannabinoids). Cannabinoids within either category exhibit some structural
similarity though comparison between categories shows marked differences in structure. The
common factor among these cannabinoids is that they are agonists at CB1 receptors and that is
the primary mechanism by which they produce their discriminative stimulus effects (Wiley et al.
1995a-d).
Phytocannabinoids

∆9-THC

CBN

CBD

∆8-THC

11-(OH)-∆9-THC

11-(OH)-∆8-THC

Figure 2.1 Chemical structures of major cannabinoids found in Cannabis sativa and related
compounds (all structures drawn by author using ChemDraw Professional 16.0. 1.4)

In addition to ∆9-THC, Cannabis sativa contains myriad cannabinoid compounds
including CBD, CBN, ∆8-THC as well as non-cannabinoid constituents such as terpenoids
(Mechoulam et al. 1972; Fischedick et al. 2010; Radwan et al. 2015). The interactions of these
compounds, psychoactive and non-psychoactive at the receptor and behavioral levels has not
been fully determined and represents a burgeoning area of research (reviewed in Russo, 2011).
∆9-THC being the primary psychoactive component of Cannabis sativa, is the most well
characterized phytocannabinoid, and was almost the exclusive focus of cannabinoid drug
discrimination research until the development of synthetic CB1 receptor agonists. Early
discrimination studies demonstrated specificity of the ∆9-THC cue in that pharmacologically
distinct compounds failed to either substitute for, or antagonize the discriminative stimulus
produced by ∆9-THC (Järbe & Henriksson, 1974; Järbe et al. 1976; Browne & Weissman, 1981).
Phytocannabinoids have been shown to display both stereoselectivity and stereospecificity in
their ability to serve as discriminative stimuli. The (+)-∆9-THC isomer does not substitute for the
(-)-isomer (i.e., stereoselectivity) whereas (-)-∆8-THC, (-)-∆9,11-THC, CBN, and ∆9-THC’s 11hydroxy metabolites all substitute in animals trained to discriminate ∆9-THC, albeit with varying
potencies (i.e., stereospecificity) (Järbe et al. 1981, 1987; Järbe & McMillan, 1980; Semjonow &
Binder, 1985). CBD, the major non-psychoactive phytocannabinoid does not substitute for ∆9THC nor does it alter ∆9-THC’s substitution patterns or rate of responding (Hiltunen & Järbe,
1986; Järbe et al. 1977, 1986; Vann et al. 2008). Much of the early literature on cannabinoid
drug discrimination was published before the existence of endogenous cannabinoid receptors
was definitively proven but the findings were consistent with a specific receptor mediated
mechanism. And indeed, it was later shown that in vivo potencies of phytocannabinoids
correlated with their binding affinities for CB1 receptors (Compton et al. 1993). In lieu of

synthetic CB1 receptor agonists, ∆9-THC discrimination has been a reliable animal model of
cannabis intoxication and the standard for studying the receptor mechanisms of cannabinoids and
predicting cannabis-like abuse potential of novel compounds.

Synthetic Cannabinoids

HU-210

AM-4030

CP55,940

CP47,497

WIN55,212-2

JWH-018

(R)-methanandamide

2-methylarachidonoyl-2'-fluoroanandamide

Fig. 2.2 Chemical structures of synthetic cannabinoid CB1 receptor agonists (all structures
drawn by author using ChemDraw Professional 16.0. 1.4)

Five major categories of synthetic cannabinoids that are classified according to their
structure include: classical, non-classical, hybrids, aminoalkylindoles, and eicosanoids (Howlett
et al. 2002; Thakur et al. 2005). Within each category, there are also multiple families of
synthetic cannabinoids (e.g., HU-#, CP-#, AM-#, WIN-#, JWH-#). Efforts to synthesize novel
cannabinoids followed after the synthetic routes for ∆9-THC established by Mechoulam and
Gaoni in 1965. The first compounds initially synthesized were classical cannabinoids (i.e.
analogs of ∆9-THC based on the dibenzopyran ring) including nabilone, levonantradol, and HU210 (Archer et al. 1977; Koe, 1981; Mechoulam et al. 1990). These compounds elicit similar
discriminative stimulus properties compared to that of ∆9-THC in drug discrimination in both
human and non-human animal models with relatively higher potencies (Young et al. 1981; Lile
et al. 2010; Hruba et al. 2014). The first non-classical cannabinoids were those of the
cyclohexylphenol (CP) series developed by Pfizer in the 1970s and 1980s as prototypical
analgesics (Melvin et al. 1984; Compton et al. 1992). Notable examples include CP47,497, its
C8 homologue (CP47,497-C8), and CP55,940. Synthetic hybrids exhibit structural features
common to both classical and non-classical cannabinoids. AM-4030, an analog of HU-210 has
both a dibenzopyran ring common among classical cannabinoids and an aliphatic hydroxyl group
common among cyclohexylphenols, Aminoalkylindoles (AAIs) are structurally dissimilar from
∆9-THC and classical synthetic cannabinoids and include compounds such as WIN55,212-2 and
JWH-018, the first synthetic cannabinoid identified in smokable “spice” blends (Gatch &
Forster, 2014). Eicosanoid synthetics were developed subsequent to the discovery of the
endocannabinoids 2-AG and AEA. Compounds such as methanandamide and methylated
fluoroanandamide (2-methylarachidonoyl-2’-fluoroanandamide) were developed for their
increased metabolic stability compared to the putative endocannabinoids (Burkey & Nation,

1997; Wiley et al. 1997). Eicosanoid derivatives have not been diverted towards abuse as other
classes of synthetic cannabinoids and have largely been used to study the discriminative stimulus
properties of the putative endocannabinoids 2-AG and AEA. As such they will be discussed with
the endocannabinoids in the following subsection. Discrimination studies have demonstrated that
synthetic cannabinoids dose-dependently substitute for ∆9-THC in both rodents and Rhesus
monkeys and have ED50 values which correlate well with their CB1 receptor binding affinities
(Compton et al. 1992; Gold et al. 1992; Lainton et al. 1995; McMahon et al. 2008; Järbe et al.
2011; Ginsburg et al. 2012). Synthetic cannabinoids have been particularly useful in establishing
structure activity relationships with respect to both in vitro and in vivo potencies (Wiley et al.
1998; 2014). But given the limited therapeutic applications of cannabinoid agonists, drug
discrimination has largely been used to assess abuse liability of novel cannabinoids.
The first wave of abused synthetic cannabinoids included structural analogs of JWH-018
(naphthoylindoles) such as JWH-073, JWH-203, JWH-204, and JWH-250 (Huffman et al. 2005;
Wiley et al. 2012). These compounds have high affinity for CB1 receptors and produce full
substitution in rodents trained to discriminate ∆9-THC via intraperitoneal administration as well
as inhalation (Vann et al. 2009; Gatch & Forster, 2014; Marshell et al. 2014). JWH-018
discrimination has been demonstrated in both rodents and Rhesus monkeys and has been the
basis for studying the discriminative stimulus properties of XLR-11 and UR-144 which were
derived from a series of tetramethylcyclopropyl ketone indoles developed by Abbot Laboratories
(Uchiyama et al. 2013; Frost et al. 2008, 2010; Rodriguez et al. 2014; Wiley et al. 2014). Both
XLR-11 and UR-144 showed dose-dependent substitution for ∆9-THC in mice and rats (Wiley et
al. 2013; Gatch & Forster, 2015). Indazole cannabinoids have begun to replace naphthoylindole
derivatives in products marketed for abuse. Indazoles which have been identified recently

include AB-CHMINACA, AB-FUBINACA, and AB-PINACA all of which fully substitute in
rodents trained to discriminate ∆9-THC from vehicle (Karinen et al. 2015; Shevyrin et al. 2014;
Uchiyama et al. 2015; Wiley et al. 2015). As new synthetic cannabinoids infiltrate the gray
market, drug discrimination remains a reliable predictor of abuse liability for cannabimimetics.

Endocannabinoids

AEA

2-AG

Fig. 2.3 Chemical structures of the endogenous cannabinoids anandamide (AEA) and 2arachidonoylglycerol (2-AG) (all structures drawn by author using ChemDraw Professional
16.0. 1.4)
Initial attempts to train rodents to discriminate AEA failed and evaluation of substitution
for ∆9-THC or CP55,940 showed mixed results. One study reported substitution in rats, but not
in mice and only at dose which significantly reduced rate of responding (Wiley et al. 1995a).
Other studies showed no substitution for ∆9-THC (Burkey & Nation, 1997; Wiley et al. 1998).
Similarly, exogenous administration of AEA does not substitute for ∆9-THC in mice (Wiley et
al. 2014). The rapid hydrolysis of AEA (Deutsch & Chin, 1993) accounted for the challenge to
achieve consistent substitution of this endogenous ligand in drug discrimination studies. The
rapid degradation of AEA was corroborated in subsequent studies showing enzymatic
inactivation of the endocannabinoids (Boger et al. 2000; Dinh et al. 2002; Cravatt et al. 2002).
Highly selective catabolic enzyme inhibitors would not become available until several years later

and so investigators relied on metabolically stable analogs of AEA. These compounds were
useful in establishing structure activity relationships to determine how the endocannabinoids,
which are eicosanoid derivatives, interact with CB1 receptors in comparison to classical, nonclassical cannabinoids and their derivatives (Adams et al. 1995, 1998). Evaluation of their
discriminative stimulus properties was also useful in exploring the physiological and behavioral
roles of the endocannabinoids.
The synthetic analog (R)-methanandamide substitutes for ∆9-THC but only in rats trained
to discriminate a relatively lower training dose (3.0mg/kg or less) whereas no generalization
occurs in rats trained to discriminate 5.6mg/kg or 30mg/kg (Burkey & Nation; 1997; Järbe et al.
1998, 2000; Wiley et al. 2011). Explanations for these dissimilar substitution patterns include the
possibility that higher dose (R)-methanandamide produces a discriminative stimulus via TRPV1
receptors based on the observation (R)-methanandamide induces TRPV1-dependent locomotor
depression (Millns et al. 2006). Another possibility is that ∆9-THC is more potent than (R)methanandamide. ∆9-THC is more potent than both O-1812 and methylated fluoroanandamide in
mice trained to discriminate O-1812 and that it produces a higher degree of substitution than
exogenous AEA in rats and monkeys trained to discriminate ∆9-THC (Wiley et al. 1997, 2004).
Despite these differences in potency and receptor mechanisms, it is apparent that AEA shares
CB1-dependent discriminative stimulus properties with ∆9-THC considering that rimonabant
completely attenuates substitution of (R)-methanandamide for ∆9-THC (Järbe et al. 2001).
Analogs of AEA have also been used as the training drug in discrimination studies (Järbe et al.
2001, 2009, 2010; Wiley et al. 2004, 2011). In rats trained to discriminate (R)-methanandamide
from vehicle, AEA produced a higher degree of substitution than ∆9-THC. Of note, these results
occurred when the interval between treatment and testing was reduced, reflecting

pharmacokinetic differences, or when the training dose of methanandamide was sufficiently high
that ∆9-THC yielded no substitution, indicating a CB1-independent mechanism (Järbe et al. 2001;
Wiley et al. 2011).
Considering the differences between ∆9-THC and AEA or its analogs, genetic approaches
have come into favor for studying the discriminative stimulus properties of endocannabinoids.
Genetic deletion of FAAH or MAGL (i.e., FAAH(-/-) and MAGL(-/-) mice) results insignificantly
elevated levels of AEA and 2-AG, respectively. This increased endocannabinoid tone imparts
distinct phenotypes allowing researchers to study the implications of the endocannabinoid
system in various physiological and behavioral processes such as metabolism, pain, and
cognition (Lichtman et al. 2004; Petrenko et al. 2014; Kishimoto et al. 2015; Pan et al. 2011;
Varvel et al. 2007; Tourino et al. 2010; Taschler et al. 2011). In particular, FAAH (-/-) mice have
been trained to discriminate exogenously administered AEA from vehicle in two-lever and Tmaze procedures (Walentiny et al. 2011; Wiley et al. 2016). O-1812 was shown to substitute in
both FAAH (-/-) and wildtype mice but was more potent in FAAH (-/-) mice suggesting that
increased brain levels of AEA contributed to the discriminative stimulus effects of O-1812
(Walentiny et al. 2015). So, in addition to pharmacological approaches using analogs of AEA,
genetic deletion of FAAH has provided further evidence that the endocannabinoids similar to ∆9THC elicit their discriminative stimulus via CB1 receptor activation.

Discriminative Stimulus Properties of Endocannabinoid Degradative Enzyme Inhibitors
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Fig. 2.4 Chemical structures of selective and dual inhibitors of FAAH/MAGL (all structures
drawn by author using ChemDraw Professional 16.0. 1.4)
Endocannabinoid discrimination studies focusing on AEA have used both
pharmacological and genetic approaches to prevent its hydrolysis. It should be reasonable to
predict that 2-AG has the similar discriminative stimulus properties as AEA given it too binds
CB1 receptors with high affinity and is present in the CNS at concentrations up to 170 times that

of AEA (Devane et al. 1992; Stella et al. 1997). SAR studies on the endocannabinoids have also
revealed that the arachidonoyl acid moiety common to both AEA and 2-AG has the least amount
of viable substitutions so the activity of either endocannabinoid at CB1 receptors would not be
expected to differ greatly (Rabinovich and Ripatti, 1991; Rich, 1993). An approach to study the
discriminative stimulus properties of 2-AG specifically is nevertheless required to make
conclusions as to the role of either endocannabinoid in the subjective effects associated with CB1
activation. Compared to FAAH (-/-) mice, MAGL (-/-) mice present certain confounders in that
they exhibit reduced CB1 receptor expression and function as well as anxiety-like behaviors
(Deng et al. 2020; Imperatore et al. 2015; Schlosburg et al. 2010). As such, MAGL(`-/-) mice
have not been evaluated as FAAH(-/-) mice in discrimination studies but the development of
selective and dual inhibitors of MAGL or FAAH has allowed investigators to study the
discriminative stimulus properties of the primary endocannabinoid hydrolytic enzymes. Both
MAGL and FAAH inhibitors induce large increases in levels of 2-AG and AEA in mouse brain,
respectively which produces behavioral effects (Fegley et al. 2005; Anh et al. 2009; Long et al.
2009; Chang et al. 2012; Niphakis et al. 2012, 2013).

Monoacylglycerol Lipase (MAGL) Inhibitors
Similar to the case of AEA, exogenous 2-AG is rapidly degraded and fails to substitute
for ∆9-THC (Matuszak et al. 2009; Wiley et al. 2014). Selective MAGL inhibitor JZL184 has
been evaluated for discriminative stimulus effects and has been shown to partially substitute for
∆9-THC in rodents (Wiley et al. 2014, 2016; Walentiny et al. 2015; Long et al. 2009). One study
showed that mice receiving JZL184 produced no greater than 25% ∆9-THC appropriate
responding although the rate of responding was reduced to less than that of vehicle (Hruba et al.

2015). Other studies similarly have shown mixed results for selective MAGL inhibitors. KML29
fails to substitute in mice trained to discriminate ∆9-THC from vehicle, suggesting that
pharmacological blockade of MAGL alone is insufficient to produce subjective effects similar to
∆9-THC (Ignatowska-Jankowska et al. 2014). MJN110 produces full substitution in mice trained
on CP55,940 and interestingly JZL184 fully substitutes for CP55,940 whereas it had only
partially substituted ∆9-THC in prior studies (Ignatowska-Jankowska et al. 2015).

Fatty Acid Amide Hydrolase (FAAH) Inhibitors
The selective FAAH inhibitors URB-597 and PF-3845 do not substitute for ∆9-THC in
rodent models of drug discrimination (Wiley et al. 2014; Hruba et al. 2015). URB-597 also fails
to substitute for ∆9-THC in Rhesus monkeys (Stewart & McMahon, 2011). Putative AEA
reuptake inhibitors AM-404 and UCM-707 similarly do not substitute for ∆9-THC in rodents
(Solinas et al. 2007). Whereas these drugs are not sufficient to substitute for cannabinoids,
combination of FAAH inhibitors and exogenous AEA produces behavioral effects. URB-597 and
AEA produce full substitution for ∆9-THC in rats and Rhesus monkeys (Solinas et al. 2007;
Stewart et al. 2011). In mice, PF-3845 in combination with AEA produces partial substitution up
to 64% ∆9-THC lever responding (Wiley et al. 2014). These results suggest that elevating
endogenous levels of AEA through FAAH inhibition are not high enough to produce subjective
cannabinoid effects but FAAH blockade reveals the cannabinoid subjective effects of AEA.

Dual MAGL & FAAH Inhibitors
Administration of the selective MAGL inhibitor JZL184 in FAAH (-/-) mice fully
substitutes for ∆9-THC in food-reinforced discrimination procedures and partially substitutes in a

water T-maze discrimination procedure (Walentiny et al. 2015; Long et al. 2009; Wiley et al.
2016). JZL184 also partially substitutes for AEA in FAAH (-/-) mice in a water T-maze
procedure. Similarly, the MAGL inhibitor KML29 produces full substitution for AEA in a foodreinforced discrimination procedure (Ignatowska-Jankowska et al. 2014). Another method for
endocannabinoid discrimination involves administration of both MAGL and FAAH inhibitors or
a single dual FAAH/MAGL inhibitor in wildtype mice. The combination of PF-3845 and
JZL184 produces full substitution for ∆9-THC in wildtype mice (Hruba et al. 2015). In the same
study it was shown that another FAAH inhibitor URB-597 in combination with JZL184 resulted
in mainly vehicle-lever responding. The disparate activities of PF-3845 and URB-597 in concert
with JZL184 could be due to species differences as URB-597 and JZL184 co-administration in
rats fully substitutes for ∆9-THC (Wiley et al. 2014). Dual FAAH/MAGL inhibitors JZL195 and
SA-57 both fully substitute for ∆9-THC in wildtype mice trained to discriminate ∆9-THC from
vehicle (Walentiny et al. 2015; Hruba et al. 2015; Long et al. 2009). SA-57 has also been used as
a training drug in wild-type mice, exhibiting both dose- and time-dependent discriminative
stimulus effects (Owens et al. 2016). Cross substitution was also demonstrated between SA-57
and CP55,940 with either drug producing full substitution for the other in mice trained to
discriminate SA-57 or CP55,940. SA-57 also produced full substitution for AEA in FAAH (-/-)
mice, indicating involvement of 2-AG in producing a CB1-mediated discriminative stimulus.
Taken together, the results from selective and dual inhibitors of FAAH and MAGL in both
wildtype and FAAH (-/-) mice provide sufficient evidence to implicate both AEA and 2-AG as
mediators of the cannabinoid discriminative stimulus in whole animals.

Discriminative Stimulus Properties of Cannabinoid Antagonists

SR141617A (rimonabant)
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Fig. 2.5 Chemical structures of CB1 receptor inverse agonists rimonabant and AM-251 (all
structures drawn by author using ChemDraw Professional 16.0. 1.4)

The pharmacological properties of the CB1 receptor antagonist/inverse agonist
rimonabant were first described in 1994 (Rinaldi-Carmona et al. 1994). In vitro, rimonabant
antagonizes CB1 receptor agonist mediated inhibition of mouse vas deferens contraction and
adenylyl cyclase activity. In vivo, rimonabant antagonizes the behavioral effects of CB1 receptor
agonists in the mouse triad assay (three of the four measures in the tetrad assay excluding
locomotor activity). Rimonabant was initially approved in the European Union as weight loss
medication t for the treatment of obesity but was recalled due to its anxiogenic and depression
side effects, as well as reports of suicide ideation, but was not approved in the U.S. (reviewed in
Sam et al. 2011). Despite its failure as a therapeutic, rimonabant has proven invaluable to the
study of cannabinoid pharmacology by providing insight into receptor mechanisms of action.
With respect to cannabinoid drug discrimination, the discriminative stimulus effects of
CB1 receptor agonists are considered CB1-dependent if rimonabant completely antagonizes their
substitution under test conditions. Antagonism of the ∆9-THC discriminative stimulus has been

demonstrated in numerous studies in several species including rodents, pigeons and monkeys
(Wiley et al 1995c, d; Mansbach et al. 1996; Pério et al. 1996; Järbe et al. 2001, 2006; Solinas et
al. 2004; McMahon et al. 2006; Walentiny et al. 2015). CB1 receptor antagonism with
rimonabant was used to demonstrate that the discriminative stimulus effects of synthetic
cannabinoids share the same CB1-dependent mechanism as ∆9-THC (Wiley et al. 1995c, d, 2013;
Pério et al. 1996; Järbe et al. 2001, 2006; DeVry & Jentzsch, 2004). The discriminative stimulus
effects of the endocannabinoids were also proven to be CB1-dependent using rimonabant.
Rimonabant reverses substitution of AEA in rats trained to discriminate methanandamide from
vehicle (Järbe et al. 2001). The discriminative stimulus effects of both selective and dual
FAAH/MAGL inhibitors in wildtype and FAAH (-/-) mice are also antagonized by rimonabant
(Solinas et al. 2007; Walentiny et al. 2011, 2015; Wiley et al. 2016; Hruba et al. 2015; Stewart
& McMahon, 2011; Long et al. 2009; Owens et al. 2016).
Given anxiogenic effects of rimonabant in humans it would seem plausible that
rimonabant alone may elicit a unique discriminative stimulus. However, attempts to establish
rimonabant discrimination in pigeons and rats through food-reinforced discrimination procedures
were unsuccessful (Mansbach et al. 1996; Pério et al. 1996). Rimonabant discrimination has
been demonstrated in rats through a taste aversion paradigm in which lithium chloride was paired
with rimonabant administration and not vehicle such that absence of the rimonabant
discriminative stimulus served as cue to the rats that the solution was safe to drink (Järbe et al.
2004, 2008). Rats on the same treatment schedule of rimonabant and vehicle without
coadministration of lithium chloride did not demonstrate acquisition of the rimonabant cue.
Substitution tests showed that AM-251, an analog of rimonabant fully substituted for rimonabant
whereas the CB2 inverse agonists SR144528 and AM-630 failed to substitute indicating that the

discriminative stimulus effects of rimonabant are CB1-mediated (Järbe et al. 2008). ∆9-THC
failed to substitute for rimonabant when given alone but when administered in combination with
rimonabant, ∆9-THC attenuated rimonabant-induced taste aversion thereby demonstrating the
opposing actions of CB1 receptor agonists and inverse agonists (Järbe et al. 2008).
Shock avoidance in Rhesus monkeys receiving daily injections of ∆9-THC is another
method for establishing rimonabant discrimination (McMahon & France 2003; McMahon,
2006). Using this model, it has been shown that discontinuation of daily ∆9-THC injections
induces rimonabant-lever responding with monkeys exhibiting overt behaviors indicative of
cannabinoid withdrawal (Stewart & McMahon, 2010). Monkeys which did not receive daily
injections of ∆9-THC did not acquire the rimonabant cue essentially making this version of
rimonabant discrimination a precipitated withdrawal model. Consistent with this observation
CB1 receptor inverse agonist AM-251 substitutes for rimonabant in Rhesus monkeys and
pretreatment with CB1 receptor agonists including AEA, ∆9-THC, CP55,940 and WIN55,212-2
prior to the rimonabant training dose attenuates rimonabant-lever responding (McMahon, 2006;
Stewart & McMahon, 2011).
Whereas rimonabant discrimination is difficult to establish under traditional procedures
applied to CB1 agonists, discrimination of its analog O-6629 has been demonstrated in wildtype
mice under FR10 food-reinforced conditions (Walentiny et al. 2013). Although O-6629 showed
dose-dependent substitution for the training dose under test conditions it did not antagonize the
discriminative stimulus of ∆9-THC in mice trained to discriminate ∆9-THC from vehicle and
there was no cross-substitution between the two drugs in mice trained to discriminate either O6629 or ∆9-THC. Rimonabant also did not substitute for nor antagonize O-6629. The only drug
which dose-dependently substituted for O-6629 was another pyrazole 3-substituent analog of

rimonabant O-6658. These findings are consistent with another study which previously showed
the series of analogs including O-6629 and O-6658 produced agonist-like effects in both
wildtype and CB1(-/-) mice which were not antagonized by rimonabant, suggesting this series
represents a novel class of compounds with non-CB1 mediated mechanisms of action (Wiley et
al. 2013).

Discriminative Stimulus Properties of CB1 Receptor Allosteric Modulators
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Fig. 2.6 Chemical structures of CB1 receptor allosteric modulators (all structures drawn by
author using ChemDraw Professional 16.0. 1.4)

Efforts to develop therapeutics which target the endocannabinoid system have largely
focused on ligands which bind CB1 receptors at the orthosteric site (i.e. the principal site of
action of CB1 receptor agonists) or which augment endocannabinoid tone through
pharmacological blockade of FAAH and/or MAGL. Advances in functional screening of GPCR
ligands in vitro has led to an increase in the availability of novel compounds which interact noncompetitively with orthosteric ligands through a distinct allosteric binding site (Rees et al.
2002). Allosteric modulators may impart functional selectivity and/or biased signaling with
respect to orthosteric ligands by inducing conformational changes of the receptor which alter
certain parameters according to the extended ternary complex model for GPCRs (reviewed in
Kenakin 2013, 2019). The first CB1 receptor allosteric modulators described were a series of
compounds developed by Organon: Org27569, Org27759, and Org29647 (Price et al. 2005).
Org27569 was shown to be a CB1 receptor negative allosteric modulator (NAM) in that it
antagonized agonist-induced [35S] GTPS binding with significant decreases in the Emax values of
CP55,940 and AEA (Price et al. 2005; Baillie et al. 2013). In vivo Org27569 decreased feeding
behavior in rats and mice and attenuation of CP55,940-induced hypothermia in rats (Gamage et
al. 2014; Ding et al. 2014). In drug discrimination however Org27569 did not alter the
discriminative stimulus effects of ∆9-THC in C57BL6/J mice or AEA in FAAH (-/-) mice
(Gamage et al. 2014). LDK1258, an analog of Org27569 similarly had no effect in drug
discrimination when administered alone and neither altered the dose response curves for
CP55,940 in C57BL6/J mice nor AEA in FAAH (-/-) mice (Mustafa, 2020). ZCZ011 has been
well characterized as a CB1 receptor positive allosteric modulator (PAM) both in vitro and in
vivo (Ignatowska-Jankowska et al. 2015). ZCZ011 displayed robust PAM activity in a battery of
in vitro functional assays. In vivo ZCZ011 potentiated the pharmacological effects of CP55,940

and AEA, showing significant increases in CP55,940-induced antinociception, catalepsy, and
hypothermia in C57BL6/J mice as well as an increase in AEA-induced hypothermia in FAAH (-/-)
mice. In drug discrimination ZCZ011 significantly increased the potency of both CP55,940 and
AEA in C57BL6/J and FAAH (-/-) respectively without eliciting any discriminative stimulus
effects or rate suppression when administered alone. ZCZ011 has garnered much interest in
recent years primarily due to its antiallodynic effects in the chronic constriction injury (CCI)
model of neuropathic pain which has spawned the development of analogs with similar
antiallodynic activity including GAT211 and ABD1236 (Slivicki et al. 2018; Tseng et al. 2019).
The discriminative stimulus effects of GAT211 and ABD1236 are not currently known.

Future Directions in Cannabinoid Drug Discrimination
Cannabinoid discrimination has demonstrated several aspects of translation efficacy
following its inception in the 1970s. Studies on ∆9-THC discrimination in several species
provided convincing evidence for the existence of an endogenous cannabinoid receptor well
before the development of in vitro assays to measure adenylyl cyclase activity the subsequent
isolation and cloning of CB1 and CB2 receptors (Järbe et al. 1974; Devane et al. 1988, 1992;
Matsuda et al. 1990; Munro et al. 1993). Following the development of synthetic CB1 receptor
agonists drug discrimination found utility in assessment of abuse liability and in SAR studies
which demonstrated correlation between CB1 receptor binding affinity and potency of
discriminative stimulus effects in vivo (Compton et al. 1992; Gold et al. 1992; Lainton et al.
1995; McMahon et al. 2008; Järbe et al. 2011; Ginsburg et al. 2012; Wiley et al. 1998; 2014;
Gatch & Forster 2014, 2015). Reliable preclinical models for cannabimimetic activity such as
drug discrimination were necessary in generating sufficient data to move CB1 receptor ligands to

clinical trials in humans. Pharmaceutical formulations of ∆9-THC such as dronabinol have been
approved by the FDA as an orexigenic for the treatment of cachexia in HIV/AIDS patients and as
an antiemetic for the treatment chemotherapy-induced nausea and vomiting (Badowski, 2017;
Wang et al. 2019). Discrimination studies involving FAAH and MAGL inhibitors were pivotal
in characterizing the behavioral effects of the endocannabinoids and conversely showing that
pharmacological blockade of these enzymes produces discernable behavioral effects. Correlation
between discriminative stimulus effects of such compounds may be useful in identifying
compounds with analgesic properties such as PF-3845 which reduces inflammatory pain and
MJN110 which reduces neuropathic pain (Ahn et al. 2009; Ignatowska-Jankowska et al. 2015;
Wilkerson et al. 2016). Drug discrimination remains a reliable measure of cannabimimetic sideeffects. Lastly, cannabinoid drug discrimination is useful assay to quantify CB1 receptor
allosteric modulation. Considering the complex neural circuitry which mediates the
discriminative stimulus effects of orthosteric CB1 receptor ligands, drug discrimination will be
useful in examining whether allosteric modulator activity in vitro translates to behavioral effects
in whole organisms. As such, drug discrimination may help identify novel compounds with
useful properties such as ZCZ011, GAT211, and ABD1236 that are both potent and resistant to
tolerance and dependence (Ignatowska-Jankowska et al. 2015; Slivicki et al 2018; Tseng et al.
2019). Aside from potential use as analgesics CB1 receptor PAMs may also have utility in the
treatment of cannabinoid use disorder (CUD) and substance use disorders involving noncannabinoid drugs of abuse (Trexler et al. 2019; Slivicki et al. 2020; Jing et al. 2014).

Chapter 3: Divergent effects of ZCZ011 analogs in mouse models of
overt cannabimimetic activity, subjective drug effects, and
neuropathic pain
Rationale
The rationale behind this study is to evaluate the 2-phenyl indole class of CB1 PAMs
represented by ZCZ011 for antiallodynic effects in the CCI model of neuropathic pain, overt
cannabimimetic effects in the tetrad assay, and subjective drug effects in the drug discrimination
paradigm. Using the tetrad and drug discrimination assay we will test analogs of ZCZ011 for
agonist activity alone and for PAM activity in combination with the orthosteric CB1 agonist
CP55,940. Considering the activity of ZCZ011 analogs in CCI, tetrad, and drug discrimination
we can examine the relationship between the antiallodynic effects, overt and subjective
cannabimimetic effects of CB1 PAMs. Should any correlation exist between CCI and drug
discrimination, then the drug discrimination paradigm may serve as a predictive model for
antiallodynic activity of CB1 PAMs.
Hypothesis
The tetrad and drug discrimination paradigms serve as predictive tools for the antiallodynic activity of CB1 PAMs in the CCI model of neuropathic pain. CB1 PAMs will produce
no overt or subjective cannabimimetic effects when administered alone but will potentiate the in
vivo pharmacological effects of the CB1 orthosteric agonist CP55,940. ZCZ011 and analogs,
which behave as CB1 PAMs will show positive correlations between their potentiation of the
pharmacological effects of CP55,940 in the triad and drug discrimination assays and their antiallodynic effects in the CCI model of neuropathic pain.

Materials and Methods
Drug Discrimination
1. Subjects
Twenty-four male and female C57BL/6J mice (Jackson Laboratory, Bar Harbor, Maine,
USA) were housed individually in clear plastic cages (18x29x30cm) with steel wire fitted
tops and wood-chip bedding in a temperature controlled (20-22º C) vivarium. Training and
test sessions were conducted at similar times during the light phase of a 12-hour light/dark
cycle. Water was available ad libitum except during training and test sessions. Mice were
maintained at 85-90% of free-feeding body weights by restricting daily rations of standard
rodent chow (supplied by Harlan labs, Frederick, MD. Rodent diet 7912). Mice were given
food ad libitum for a period of at least two weeks once every six months. Animals used in
this study were cared for in accordance with the guidelines of the Institutional Animal Care
and Use Committee of the Virginia Commonwealth University and the ‘Guide for the Care
and Use of Laboratory Animals’ (National Research Council, 1996).
2. Apparatus
Experimental sessions were conducted in sound- and light-attenuated operant
conditioning chambers (Med Associates, St. Albans, VT), Each chamber (18x18x18 cm) was
equipped with a house light, two nose-poke apertures, and a recessed food receptacle
centered between the apertures that was connected to a pellet hopper. Fans in the chambers
provided ventilation and white noise. The house light remained off during training and test
sessions. The chambers were connected to a computer running Med-PC software (Med
Associates) used for scheduling contingencies and recording data.
3. Procedures

3.1. Overnight interactive FR training
Mice were placed in designated operant chambers and trained to respond at one aperture
according to a fixed ratio (FR) 1 schedule of reinforcement. A food pellet reinforcement was
delivered after every response. After one hour or 50-100 reinforcements the FR value was
increased to FR2 for the remainder of the overnight session. Overnight training was
concluded after 10-12 hours and the aperture with the most responses for each mouse was
designated as the preferred-side aperture.
3.2. Interactive FR10 training
Mice were placed in designated operant chambers and trained to respond at their
preferred-side aperture at a FR2 schedule of reinforcement. The FR value was gradually
increased to the final FR10 schedule of reinforcement in which 10 consecutive responses
were required for delivery of food reinforcement. After mice were trained at one aperture, the
contingency requirements were switched to the other aperture. Training at the second
aperture proceeded identically to that at the first aperture. When responding at the second
aperture under a FR10 schedule of reinforcement was acquired, discrimination training was
initiated.
3.3. Discrimination training
Mice were trained to respond at one aperture following administration of 0.1 mg/kg
CP55,940 s.c. (30-min pretreatment time) and to respond at the other lever following vehicle
s.c. injection according to a FR10 schedule of reinforcement. Each response at the incorrect
aperture reset the response requirement at the correct aperture. Daily injections were
administered on a double alternation sequence of CP55,940 and vehicle (e.g. drug, drug,
vehicle, vehicle). Daily 15-min training sessions were held until the mice had met three

criteria during 9 of 10 consecutive training sessions: (1) the first completed FR10 (FFR) was
at the correct aperture, (2) ≥80% of the total responding was at the correct aperture and (3)
the rate of responding was ≥10min-1. When these criteria were met, acquisition of the
discrimination was established, after which substitution and combination testing began.
3.4. Substitution and Combination tests
Discrimination training was continued 5-7 days per week with stimulus substitution or
combination tests occurring up to two days per week with no less than 72 hours between
tests. To be eligible for testing, mice must have passed discrimination criteria during their
last drug and vehicle training sessions. Prior to substitution or combination tests,
generalization curves for CP55,940 were generated for all mice. During test sessions,
responses at either aperture delivered reinforcement according to an FR10 schedule.
Substitution and combination tests were conducted with several 2-phenyl indole analogs of
ZCZ011 including GAT211, LDK1747, and LDK1752. For substitution tests, the test
compound (40 mg/kg) or vehicle i.p. was administered 30-min prior to the test session. For
combination tests, the test compound (40 mg/kg) or vehicle i.p. was administered 15-min
prior to treatment with CP55,940 (0.01, 0.03, 0.056, 0.1, 0.3, or 1.0 mg/kg) or vehicle s.c.
and 45-min prior to the test session. To ensure maintenance of CP55,940’s discriminative
stimulus effects, control tests with the training dose of CP55,940 and vehicle were repeated
before conducting substitution or combination tests with novel compounds.
4. Drugs
ZCZ011 and its analogs have been previously characterized in vitro with CP55,940
(Table 1.1). Therefore CP55,940 will serve as the orthosteric probe for the present studies.
CP55,940 was supplied by the National Institute on Drug Abuse (NIDA). GAT211,

LDK1747, and LDK1752 were synthesized at the Rangel College of Pharmacy Health
Science Center at Texas A&M University (Kingsville, TX, USA). Drugs were dissolved via
sonication in a vehicle consisting of ethanol, Alkamuls-620 (Sanofi-Aventis) and saline in a
ratio of 1:1:18. All drugs were administered at an injection volume of 10𝜇l per gram of body
mass. Subcutaneous route of administration was used for CP55,940 and vehicle injections in
the drug discrimination studies. Intraperitoneal route of administration was used for all other
drugs.
5. Dose selection
ZCZ011 and all analogs were tested at a dose of 40 mg/kg in the drug discrimination,
tetrad, and CCI experiments. ZCZ011 is analgesic in the CCI model at 40 mg/kg and so
that dose will serve as the basis for comparison for ZCZ011 analogs.
6. Data analysis
Acquisition indices were the percentage of animals meeting the discrimination training
criteria (1.3.3). For each test session, the percentage of responses at the drug-side aperture
and response rate (responses/min) were calculated. Mice that responded less than 10 times
during a test session did not receive a reinforcement and so were excluded from analysis of
aperture selection. All mice were included in analysis of response rate. Full substitution for
CP55,940 was defined as ≥80% CP55,940-appropriate responding. Partial substitution for
CP55,940 was defined as ≥20% and <80% CP55,940-appropriate responding.
Tetrad
1. Subjects
12 Male and female C57BL/6J mice (Jackson Laboratory, Bar Harbor, Maine,
USA) were housed in clear plastic cages (18x29x30cm) with steel wire fitted tops and

wood-chip bedding in a temperature controlled (20-22º C) vivarium. Food and water
were available ad libitum. Mice were tested during the day on a normal 12-hour lightdark cycle. Animals used in this study were cared for in accordance with the guidelines of
the Institutional Animal Care and Use Committee of the Virginia Commonwealth
University and the ‘Guide for the Care and Use of Laboratory Animals’ (National
Research Council, 1996).
2. Procedures
2.1. Baseline measurements
Prior to injection, mice were weighed and baseline measurements were taken of
tail withdrawal latency and rectal temperature. Mice were injected following baseline
measurements and then tested 30-min later in the order which follows.
2.2. Locomotor activity assessment
Locomotor effects were assessed by placing mice in clear Plexiglas enclosures
(43x21x20 cm) housed in sound- and light-attenuated chambers equipped with a house
light and Fire-i™ digital cameras (Unibrain, San Ramon, CA, USA). Fans in the
chambers provided ventilation and white noise. The house light remained on during the
300 second test sessions. The chambers were connected to a computer running Anymaze
(Stoelting, Wood Dale, IL) software for session parameter control and data collection.
Distance traveled (m), time immobile (s), and mean speed were recorded over 300
seconds.
2.3. Catalepsy bar test
Catalepsy was assessed on a metal bar attached to a ring-stand placed 4.5 cm
above the platform. The mice were placed with their front paws resting on the bar and

time spent immobile was measured over 60 seconds. If the mouse climbed onto the bar
or moved from its fixed position it was replaced for a maximum of three tries.
2.4. Warm-water tail withdrawal assay
Thermal nociceptive behavior was assessed by immersing the distal portion
(approximately 1 cm) of the mice tails in a water bath held at 52º C. Tail withdrawal
latency was measured up to a maximum of 10 seconds. Data were expressed as percent
change from baseline or maximum percent effect (%MPE) according to the formula:
%MPE = [(test latency – preinjection latency) / (10 – preinjection latency)] ×100.
2.5. Rectal temperature
Hypothermic effects were assessed by measuring rectal temperature with a
thermometer probe (Physitemp Instruments, Clifton, NJ) inserted 2 cm into the rectum.
Data were expressed as a change in temperature (ΔT) from baseline measured in ºC.
3. Drugs
See Drug Discrimination section 4.0
4. Dose selection
See Drug Discrimination section 5.0

Chronic Constriction Injury (CCI) Model of Neuropathic Pain
1. Subjects
See Tetrad section 2.1
2. Apparatus
Mice were placed individually in Plexiglas cylinders (8 cm diameter, 15 cm
height) situated over a wire screen mesh surface. A blanket was draped over the setup to

blind mice to visual distractions in the laboratory. Mice were observed from below the
surface of the screen mesh.
3. Procedures
3.1. Sciatic nerve ligation
Surgery was performed according to techniques described previously (Bennett &
Xie et al. 1988; Ignatowska-Jankowska et al. 2015). Mice were anesthetized with
isoflurane and the surgical site was prepared using aseptic technique. The sciatic nerve
was isolated and loosely ligated. The sham surgery was performed identically but
without nerve ligation.
3.2. Von Frey test for mechanical hypersensitivity
Mechanical hypersensitivity following surgery was measured using von Frey
calibrated filaments as previously described (Murphy et al. 1999). Von Frey filaments
were applied to the hind paws ipsilateral and contralateral to the surgery at 30-min
postinjection. The stimulus threshold which evoked a response as defined by either
lifting, licking, or shaking of the paw was recorded.
4. Drugs
See Drug Discrimination section 4.0
5. Dose selection
See Drug Discrimination section 5.0

Results

Evaluation of ZCZ011 analogs in the tetrad assay
The tetrad assay was performed in a series of four experiments (detailed in section 2.2).
ZCZ011 analogs did not elicit full cannabimimetic effects in the tetrad assay. LDK1729 (40
mg/kg) suppressed locomotor activity with respect to distance traveled and time spent immobile
(p < 0.01; unpaired t-test) (Table 3.1) and showed small but significant hypothermic effects at 30
min post-administration (F (2, 20) = 9.292; P = 0.001). However, LDK1729 (40 mg/kg) did not
produce significant cataleptic or antinociceptive effects. The remaining analogs (ZCZ011,
ABD1236, GAT211, LDK1730, LDK1747, LDK1750, LDK1752) did not produce significant
effects in any of the tetrad measures (Table 3.1).

Table 3.1 Summary of ZCZ011 analog activity in the tetrad assay
Locomotor

Catalepsy (s)

Tail withdrawal (s)

Body temperature (°C)

immobility (s)

VEH

ZCZ011

Post-

Pre-

Post-

Pre-

Post-

Pre-

Post-

injection

injection

injection

injection

injection

injection

injection

6.01 ± 1.80

0

0

1.71 ±

2.08 ±

36.30 ±

37.61 ±

0.10

0.20

0.26

0.19

1.81 ±

2.06 ±

35.88 ±

37.55 ±

0.13

0.10

0.20

0.09

17.16 ± 2.60

0

0

VEH

ABD1236

VEH

GAT211

VEH

LDK1729

VEH

LDK1730

VEH

7.55 ± 3.17

3.38 ± 0.91

5.22 ± 3.84

4.97 ± 1.65

3.87 ± 2.33

27.28 ± 11.61

11.33 ± 3.05

31.60 ± 18.66

8.63 ± 2.20

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

1.71 ±

1.60 ±

37.75 ±

37.62 ±

0.28

0.24

0.15

0.10

1.97 ±

1.84 ±

37.62 ±

37.38 ±

0.34

0.29

0.23

0.13

1.33 ±

1.06 ±

36.78 ±

37.47 ±

0.13

0.08

0.26

0.29

1.25 ±

1.25 ±

36.93

37.82± 0.12

0.14

0.12

±0.26

1.18 ±

1.06 ±

37.95 ±

37.83 ±

0.10

0.12

0.16

0.12

1.08 ±

1.42 ±

37.93 ±

36.87 ±

0.11

0.15

0.13

0.28*

1.67 ±

2.12 ±

37.72 ±

37.37 ±

0.15

0.24

0.20

0.16

1.51 ±

2.09 ±

37.72 ±

36.98 ±

0.18

0.31

0.15

0.35

0.75 ±

0.86 ±

38.23 ±

38.32 ±

0.06

0.06

0.17

0.10

LDK1747

VEH

10.93 ± 4.16

7.67 ± 2.03

LDK1750

VEH

16.33 ± 10.26

6.22 ± 1.730

LDK1752

5.38 ± 0.95

0

0

0

0

0

0

0

0

0

0

0.91 ±

1.01 ±

38.35 ±

38.23 ±

0.10

0.173

0.17

0.07

1.67 ±

1.91 ±

37.97 ±

37.78 ±

0.10

0.10

0.16

0.10

2.10 ±

2.26 ±

37.65 ±

37.00 ±

0.26

0.24

0.13

0.16

0.92 ±

0.89 ±

37.90 ±

37.57 ±

0.24

0.09

0.21

0.38

0.84 ±

1.19 ±

37.93 ±

37.65 ±

0.12

0.19

5.86

0.15

(*) indicates significant results

Acquisition and discrimination of the CP55,940 discriminative stimulus shows no sex differences
Cannabinoid drug discrimination studies in rodents have traditionally used male subjects.
Therefore, the first set of experiments examined whether there were sex differences in
acquisition of CP55,940 discrimination. Discrimination acquisition curves were constructed for
male and female C57BL/6J mice training to discriminate CP55,940 (0.1 mg/kg) from vehicle
(Fig. 3.1A). All mice acquired the discriminative stimulus of CP55,940 (0.1 mg/kg) within 90
training days. Unpaired t-test of male and female learning curves (Fig. 3.1B) showed no
significant difference in acquisition according to sex (t=1.613). Dose-response curves for

responding on the CP55,940 associated aperture and response rates were constructed using
CP55,940 (0.01-1.0 mg/kg). Responding on the drug aperture was statistically significant at 0.1
mg/kg (CP55,940 main effect: F (DFn, DFd) 3.668 (5, 95); P < 0.0001; Fig. 3.1C). Rate of
responding was significantly decreased at and above 0.3 mg/kg (CP55,940 main effect: F (DFn,
DFd) 8.685 (5, 122); P <0.0001; Fig. 3.1E). The data were also plotted according to sex (Fig.
3.1D, F) and analyzed using two-way ANOVA. No significant difference was observed between
males and females for CP55,940 drug-like responding or response rates (interaction between sex
and dose: F (5, 90) = 0.5777, P = 0.7169; CP55,940 main effect: F (5, 90) = 32.19, P < 0.0001;
sex main effect: F (1, 90) = 2.585, P = 0.1114).
(A)

(B)

(C)

(D)

(E)

(F)

Figure 3.1 Male and female C57BL6/J mice show identical acquisition rates of CP55,940 in the drug
discrimination paradigm similar generalization curves of CP55,940 (A) Discrimination learning curve shows
100% of total C57BL/6J mice acquired the discriminative stimulus of CP55,940 within 90 training days. (B)
Discrimination learning curve for males and females reveal no sex differences for acquisition of the CP55,940
discriminative stimulus. (C) CP55,940 (0.01-1.0 mg/kg) produces a dose-dependent discriminative stimulus in
C57/BL6J mice. (D) No sex differences exist for CP55,940 (0.01-1.0 mg/kg) drug-like responding (E) CP55,940
(0.01-1.0 mg/kg) produces dose-dependent suppression of response rates in C57BL6/J mice. (F) No sex
differences exist for CP55,940 (0.01-1.0 mg/kg) effect on response rates. N = 23 C57BL6/J mice; n = 11-12 mice
per sex. All data were collected 30 min after treatment administration and reported as mean ± SEM. Data were
analyzed via unpaired t-test (B), one-way ANOVA (C) & (D), or two-way ANOVA (D) & (F).

Evaluation of GAT211, LDK1747, and LDK1752 substitution for CP55,940 in the drug
discrimination paradigm
ZCZ011 analogs were screened for subjective cannabimimetic effects by measuring
substitution for the discriminative stimulus of CP55,940 (0.1 mg/kg) in the drug discrimination
paradigm. GAT211 (20-40 mg/kg) did not substitute for CP55,940 (0.1 mg/kg) and had no effect
on response rates at 30 min post-injection (Fig 3.2A). LDK1747 (40 mg/kg) did not substitute for
the discriminative stimulus of CP55,940 (0.1 mg/kg) and had no effect on response rates at 45

min post-injection (Fig. 3.2B). LDK1752 (40 mg/kg) did not substitute for CP55,940 (0.1 mg/kg)
and had no effect on response rates at 45 min post-injection (Fig. 3.2C).
(A)

(B)

(C)

Figure 3.2 Evaluation of GAT211, LDK1747, and LDK1752 substitution for CP55,940 in the drug discrimination
paradigm. (A) GAT211 (20 or 40 mg/kg) did not substitute for the discriminative stimulus of CP55,940 (0.1
mg/kg) and did not suppress the rate of responding. (B) LDK1747 (40 mg/kg) did not substitute for the
discriminative stimulus of CP55,940 (0.1 mg/kg) and did not alter the rate of responding. (C) LDK1752 did not
substitute for the discriminative stimulus of CP55,940 (0.1 mg/kg) and did not alter the rate of responding. All
data were collected 30 min after treatment and reported as mean ± SEM. All data were analyzed using one-way
ANOVA.

Evaluation of ZCZ011 analogs in augmenting the pharmacological effects of CP55,940: triad
assay
ZCZ011 analogs were tested in combination with CP55,940 in the triad assay to screen
for allosteric modulator effects. ZCZ011 (40 mg/kg) potentiated the cataleptic, antinociceptive,
and hypothermic effects of CP55,940 (0.3 mg/kg) (Fig. 3.3A). ABD1236 (40 mg/kg) potentiated
CP55,940-induced antinociception and hypothermia (Fig. 3.3B). GAT211 (20-40 mg/kg)
potentiated CP55,940-induced catalepsy, antinociception, and hypothermia (Fig. 3.3C).
LDK1729 (40 mg/kg) potentiates CP55,940-induced hypothermia (Fig. 3.3D). LDK1730 slightly
potentiated CP55,940-induced hypothermia with significance at 1.0 mg/kg CP55,940 (Fig. 3.3E)
LDK1747 (40 mg/kg) potentiated CP55,940-induced antinociception and hypothermia (Fig.
3.3F). LDK1750 (40 mg/kg) does not affect the dose-effect relationships of CP55,940 (Fig.
3.3G). LDK1752 (40 mg/kg) produced a small but significant potentiation of CP55,940-induced
catalepsy (F (3, 30) = 4.013; P <0.0001; Fig. 3.3H), but only at 0.3 mg/kg CP55,940. LDK1752
(40 mg/kg) failed to alter the dose-response relationships of CP55,940 (0.1-3.0 mg/kg) for
antinociception and hypothermia (Fig. 3.3H). The ED50 values of CP55,940 as well as potency
ratios were calculated for each measure of the triad assay. Table 3.2 shows the ED50 and potency
ratio comparisons between vehicle and ZCZ011 analog pretreatment groups.
(A)

(B)

(C)

(D)

(E)

(F)

(G)

(H)

Figure 3.3 Evaluation of ZCZ011 analogs in combination with CP55,940 in the triad assay. (A) ZCZ011 (40
mg/kg) potentiates CP55,940-induced catalepsy, antinociception, and hypothermia. (B) ABD1236 (40 mg/kg)
potentiates CP55,940-induced antinociception and hypothermia. (C) GAT211 (20-40 mg/kg) potentiates
CP55,940-induced catalepsy, antinociception, and hypothermia. (D) LDK1729 (40 mg/kg) slightly potentiated
CP55,940-induced antinociception. (E) LDK1730 (40 mg/kg) slightly potentiated CP55,940 induced hypothermia
(F) LDK1747 (40 mg/kg) potentiates CP55,940-induced antinociception and hypothermia. (G) LDK1750 (40
mg/kg) does not affect the dose-effect relationships of CP55,940. (H) LDK1752 (40 mg/kg) slightly potentiated
CP55,940-induced catalepsy with significance at 0.3 mg/kg dose of CP55,940 but did not alter the antinociceptive
or hypothermic effects of CP55,940 (0.1-3.0 mg/kg). All data are reported as mean ± SEM and were analyzed via
two-way ANOVA. Experiments (A-G) conducted by Julien Dodu and Mohammed Mustafa.

Table 3.2 Effects of ZCZ011 analogs on CP55,940 ED50 and potency ratio values in the triad assay
ED50 (CL 95%) CP55,940 (mg/kg)

Compound
ZCZ011

ABD1236

GAT211

LDK1729

LDK1730

Measure

Potency Ratio (CL 95%)

Vehicle

PAM

0.55 (0.36-0.85)

0.31 (0.21-0.46)

1.66 (0.95-3.17)

antinociception 0.42 (0.29-0.63)

0.30 (0.21-0.42)

1.40 (0.84-2.48)

catalepsy

hypothermia

1.19 (0.93-1.53)

0.44 (0.35-0.55)

2.08 (1.38-3.36)

catalepsy

0.36 (0.28-0.46)

0.41 (0.31-0.55

0.89 (0.65-1.22)

antinociception 0.58 (0.40-0.84)

0.18 (0.12-0.27)

3.26 (1.77-8.49)

hypothermia

0.35 (0.31-0.41)

0.22 (0.18-0.27)

1.57 (1.23-2.04)

catalepsy

0.53 (0.34-0.84)

0.47 (0.26-0.83)

1.12 (0.77-1.64)

antinociception 0.57 (0.42-0.79)

0.21 (0.17-0.27)

2.48 (1.63-4.03)

hypothermia

0.33 (0.27-0.39)

0.14 (0.12-0.18)

1.87 (1.45-2.45)

catalepsy

0.53 (0.37-0.78)

0.48 (0.33-0.71)

1.15 (0.72-1.86)

antinociception 0.44 (0.28-0.51)

0.38 (0.28-0.51)

1.16 (1.01-1.33)

hypothermia

0.29 (0.23-0.37)

0.18 (0.14-0.24)

1.54 (1.17-2.04)

catalepsy

0.33 (0.19-0.58)

0.43 (0.21-0.87)

0.88 (0.33-2.32)

antinociception 0.13 (0.05-0.36

0.18 (0.06-0.51)

0.71 (0.15-3.32)

LDK1747

LDK1750

LDK1752

hypothermia

0.33 (0.21-0.52)

0.14 (0.10-0.19)

2.31 (1.41-3.86)

catalepsy

0.28 (0.21-0.37)

0.21 (0.14-0.31)

1.32 (0.84-2.11)

antinociception 0.40 (0.30-0.55)

0.33 (0.24-0.44)

1.25 (0.89-1.77)

hypothermia

0.26 (0.22-0.31)

0.16 (0.13-0.19)

1.58 (1.35-1.84)

catalepsy

0.32 (0.17-0.60)

0.63 (0.38-1.09)

1.80 (0.71-4.94)

antinociception 0.07 (0.04-0.14)

0.04 (0.02-0.09)

0.78 (0.24-2.49)

hypothermia

0.13 (0.09-0.18)

0.13 (0.10-0.16)

0.98 (0.67)

catalepsy

0.53 (0.29-0.96)

0.35 (0.13-0.91)

0.56 (0.31-1.00)

antinociception 0.48 (0.38-0.61)

0.40 (0.31-0.51)

0.82 (0.60-1.13)

0.32 (0.25-0.40)

0.85 (0.60-1.19)

hypothermia

0.36 (0.28-0.46)

Evaluation of GAT211, LDK1747, and LDK1752 in combination with CP55,940 in the drug
discrimination paradigm
In the combination studies, GAT211 (40 mg/kg) did not alter the dose-response
relationship of CP55,940 (0.01-1.0 mg/kg) in drug-like responding or response rates at 45 min
post-injection (Fig. 3.4A, B). Separate analysis of male and female data using 2-way ANOVA
showed no significant difference in drug-like responding (Table 3.3) or response rates (Table
3.4) following GAT211 (40 mg/kg) administration. LDK1747 (40 mg/kg) did not alter the doseresponse relationship of CP55,940 (0.01-1.0 mg/kg) in drug-like responding or response rates at
45 min post-injection (Fig. 3.4C, D). Separate analysis of male and female data using 2-way

ANOVA showed no significant difference in drug-like responding (Table 3.3) or response rates
(Table 3.4) following LDK1747 (40 mg/kg) administration. LDK1752 (40 mg/kg) slightly
potentiated the discriminative stimulus of CP55,940 with significance at 0.03 mg/kg (interaction
between LDK1752 and CP55,940: F (2, 10) = 6.486, P = 0.0156; CP55,940 main effect: F (2,
10) = 26.64, P < 0.0001; LDK1752 main effect: F (1, 5) = 5.673, P = 0.0630; Fig. 3.4E).
LDK1752 (40 mg/kg) did not alter the dose-response relationship of CP55,940 with respect to
response rates (Fig. 3.4F). Separate analysis of male and female data using 2-way ANOVA
showed no significant difference in drug-like responding (Table 3.4) or response rates (Table
3.4) following LDK1752 (40 mg/kg) administration.
(A)

(B)

(C)

(D)

(E)

(F)

Figure 3.4 Evaluation of GAT211, LDK1747, and LDK1752 in combination with CP55,940 in the drug
discrimination paradigm. (A) GAT211 (40 mg/kg) did not alter the dose-response curve of CP55,940 drug-like
responding (B) GAT211 (40 mg/kg) did not alter the dose-response curve of CP55,940 rate of responding. (C)
LDK1747 (40 mg/kg) did not alter the dose-response curve of CP55,940 drug-like responding (D) LDK1747 (40
mg/kg) did not alter the dose-response curve of CP55,940 rate of responding. (E) LDK1752 potentiated CP55,940
drug-like responding with significance at 0.03 mg/kg (F) LDK1752 (40 mg/kg) did not alter the dose-response
curve of CP55,940 (0.01-1.0 mg/kg) in rate of responding.

Table 3.3 Summary of two-way ANOVA between sex and allosteric pretreatment in drug-like responding
Interaction

CP55,940 main effect

Sex main effect

F (DFn,

P

P value

F

P

P value

F (DFn,

P

P value

DFd)

value

summary

(DFn,

value

summary

DFd)

value

summary

5, 17 =

<

****

1, 17 =

0.7499

ns

18.07

0.0001

4, 8 =

0.0017

0.9146

ns

0.7753

ns

DFd)
GAT211

5, 17 =

0.3852

ns

1.123
LDK1747

4, 8 =

0.9353

ns

0.1930
LDK1752

2, 4 =
0.0869

0.7499
**

12.38
0.9185

ns

2, 4 =
18.53

1, 2 =
0.01468

0.0095

**

1, 2 =
0.1064

Table 3.4 Summary of two-way ANOVA between sex and allosteric pretreatment in rate of responding
Interaction

CP55,940 main effect

Sex main effect

F (DFn,

P

P value

F

P

P value

F (DFn,

P

P value

DFd)

value

summary

(DFn,

value

summary

DFd)

value

summary

6, 21 =

<

****

1, 21 =

0.7673

ns

22.47

0.0001

6, 12 =

0.0037

0.3143

ns

0.9088

ns

DFd)
GAT211

6, 21 =

0.2619

ns

1.397

LDK1747

6, 12 =

0.5495

ns

0.8609
LDK1752

6, 12 =
1.111

0.08988

**

6.184
0.4107

ns

6, 12 =
7.358

1, 2 =
1.775

0.0018

**

1, 2 =
0.01679

Evaluation of ZCZ011 analogs in the chronic constriction injury (CCI) model of neuropathic
pain
The ZCZ011 analogs, ABD1236, GAT211, LDK1729, LDK1730, LDK1747, LDK1750,
and LDK1752 (Fig. 3.5) were evaluated in the CCI model of neuropathic pain. ZCZ011,
ABD1236, and GAT211 produced full reversal of allodynia, whereas the LDK series of
compounds lacked activity. ZCZ011 (40 mg/kg) produces time-dependent reversal of allodynia
for up to twelve hours following administration and this effect is not subject to tolerance under
repeated administration (Fig. 3.6A). ABD1236 (40 mg/kg) produces significant increases in paw
withdrawal thresholds for up to four hours post-administration (Fig. 3.5). GAT211 (40 mg/kg)
was shown to reverse allodynia for up to eight hours following administration (Fig. 3.5). The

remaining analogs LDK1729, LDK1730, LDK1747, LDK1750, and LDK1752 at 40 mg/kg had
no effect on paw withdrawal thresholds at any of the time points tested (Fig. 3.5).
(A)

(B)

(C)

(B)

(D)

(E)

(F)

(G)

(H)

Figure 3.5 Evaluation of ZCZ011 analogs in the CCI model of neuropathic pain. (A) ZCZ011 (40 mg/kg)
reverses allodynia up to 12 hours post administration and maintains its effect following repeated administration.
(B) ABD1236 (40 mg/kg) reverses allodynia up to 4 hours post administration. (C) GAT211 (40 mg/kg) reverses
allodynia up to 8 hours post administration. (D-H) LDK series of ZCZ011 analogs fail to reverse allodynia at a
dose of 40 mg/kg. n = 6-8 C57BL6/J mice per treatment group; mixed sex. All data are reported as mean ± SEM.
Surgeries and experiments conducted by Lauren Moncayo and Rebecca Moncayo.

Chapter 4. Discussion and Conclusions
Summary of Results
The results obtained from studies on GAT211, LDK1747 and LDK1752 are summarized
along with those of previous in vivo experiments on ZCZ011 and its analogs in Table 4.1.
Almost no activity was seen for any compound in the tetrad assay except for minor locomotor
suppression and hypothermic effects following LDK1729 administration. In the triad assay, only
ZCZ011 and GAT211 produced leftward shifts in the dose-response relationship of CP55,940 for
all three measures. ABD1236 and LDK1747 did not alter the cataleptic effects of CP55,940.
LDK1729 and LDK1730 potentiated only hypothermic effects of CP55,940, whereas LDK1752
potentiated catalepsy, only. ZCZ011 was the only 2-phenyl indole characterized in drug
discrimination prior to this study. This study examined GAT211, LDK1747, and LDK1752 in
the drug discrimination paradigm. ZCZ011 analogs all failed to substitute for the discriminative
stimulus of CP55,940 and had no effect on response rates. In the combination studies, only
ZCZ011 and LDK1752 potentiated the discriminative stimulus effects of CP55,940 and none of
the compounds had any effect on response rates. In the CCI model of neuropathic pain, only
ZCZ011, ABD1236, and GAT211 had antiallodynic activity whereas the LDK series of
compounds were ineffective. In summary, ZCZ011 is the only 2-phenyl indole, which elicits
leftwards shifts in the CP55,940 dose response relationships in the triad assay and drug
discrimination paradigm, as well as reduces CCI-induced allodynia.
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Compound

CCI Model of
Neuropathic Paina

Tetradb

Triadc [CP55,940]

ZCZ011

full reversal

no effect

potentiation (3/3)

Drug Discriminationd
no substitution or rate
suppression
potentiates DLR%

ABD1236

potentiation (2/3); no
effect on catalepsy

GAT211

potentiation (3/3)

not tested
no substitution or rate
suppression
no effect on CP55,940 dose
response

LDK1729

no effect

locomotor
suppression,
hypothermia

potentiates
hypothermia

not tested

LDK1730

no effect

potentiates
hypothermia

not tested

LDK1747

no effect

potentiation (2/3); no
effect on catalepsy

no substitution or rate
suppression
no effect on CP55,940 dose
response

LDK1752

no effect

potentiates catalepsy

no substitution or rate
suppression
potentiates DLR% without
effect on response rates

a.
Surgeries and experiments conducted by Lauren Moncayo and Rebecca Moncayo.
b.
(c) (d) Experiments conducted by Julien Dodu and Mohammad Mustafa. GAT211, LDK1747, and
LDK1752 studies were conducted by the author.

In Vivo activity of ZC011 analogs
Before interpreting the results, the rationale behind dose selection and use of male and
female subjects in the drug discrimination paradigm should be discussed. The dose chosen for
each CB1 PAM evaluated was based on the effective dose of ZCZ011 in previous studies that
produced full reversal of allodynia in the CCI model (i.e., 40 mg/kg; i.p.) (Ignatowska-

Jankowska et al. 2015). At this dose, ZCZ011 also produced leftward shifts in the dose-response
curves of CP55,940 in the triad assay and drug discrimination paradigm and so this parent
compound was considered the gold standard by which to compare the other analogs. Therefore,
should an analog not exhibit the same degree of PAM activity in vivo as ZCZ011, one could test
a higher dose but having to do so would mean the same compound has no therapeutic advantage
over ZCZ011. Furthermore, solubility presents more of a challenge when preparing doses greater
than 40 mg/kg. Drug discrimination studies have largely used only male subjects however sex
differences in subjective responses to cannabinoids have been demonstrated in humans and
rodents. In humans, females have reported greater subjective responses to ∆9-THC at 3 mg (p.o.)
than males, whereas males reported greater sensitivity at higher doses of ∆9-THC (15 mg/kg p.o.)
(Fogel et al. 2017). Female Sprague-Dawley rats learn to discriminate ∆9-THC faster and at
lower doses (1 mg/kg vs 3 mg/kg) than their male counterparts (Wiley et al. 2017). One study
using C57BL6/J trained to discriminate ∆9-THC (0.56 mg/kg) for food reinforcement showed
that CP55,940 was more potent in male subjects than in females (Wiley et al. 2019). Therefore, it
was important to evaluate sex differences in the cannabinoid discrimination paradigm used in
this study. Here, we report that the potency of the CP55,940 discriminative stimulus did not
differ between male and female C57BL6/J mice and response rates similarly showed no
differences (Table 4.1).

ZCZ011 analogs do not elicit overt or subjective cannabimimetic effects
The purpose of the tetrad assay was to screen ZCZ011 analogs for CB1 agonist-mediated
cannabimimetic effects. Consistent with the assertion that PAMs do not activate the orthosteric
site of their respective receptors, ZCZ011 analogs do not elicit the full tetrad set of behavioral

effects seen with CB1 agonists. LDK1729 elicited only minor locomotor and hypothermic effects
and lacked activity in the other behavioral measures. The drug discrimination paradigm was used
to screen ZCZ011 analogs for discriminative stimulus effects similar to CP559,940. When tested
for substitution, none of the ZCZ011 analogs substituted for the discriminative stimulus of
CP55,940 (0.1 mg/kg). Accordingly, ZCZ011 analogs do elicit in vivo pharmacological effects
associated with CB1 orthosteric agonists. These results seem consistent with the activity of
ZCZ011 analogs in vitro. The Emax values for ZCZ011 analogs with respect to cAMP-inhibition
and ß-arrestin recruitment would indicate these compounds have some agonist activity, however
their EC50 values are orders of magnitude higher in comparison to CP55,940 (Table 1.1).
ZCZ011 analogs are then considerably lacking in potency at the orthosteric site of CB1 receptors
compared to direct agonists both in vitro and in vivo, as would be expected for purported CB1
PAMs. Whether any ZCZ011 analog acts at the orthosteric site or functions as an allosteric
agonist at CB1 receptors in vitro, it is not behaviorally relevant as cannabimimetic effects were
not observed in the tetrad assay or substitution tests.

Activity comparisons between ZCZ011 analogs across behavioral paradigms
The overall purpose of this study was to examine the relationship between the
antiallodynic, overt and subjective cannabimimetic effects of CB1 PAMs represented by
ZCZ011. According to the hypothesis, antiallodynic analogs of ZCZ011 should have also elicited
leftward shifts of the CP55,940 dose-response curves in the tetrad assay and drug discrimination
paradigm. In other words, positive allosteric modulation of the overt and subjective effects of
cannabinoids was expected to be positively associated with reversal of allodynia in the CCI

model of neuropathic pain. The data from this study did not suggest a relationship among the
CCI, tetrad, and drug discrimination paradigms for CB1 PAMs.
On the other hand, three compounds that produced antinociception in the CCI assay also
augmented the pharmacological effects of CP55,940 in the triad assay. In the triad assay,
ZCZ011, ABD1236, and GAT211 had in general greater effects on CP55,940 potency than the
LDK series. LDK1747, similar to ABD1236, potentiated CP55,940-induced antinociception and
hypothermia however LDK1747 was less potent by comparison. These results suggest that CB1
PAMs, which augment the overt cannabimimetic effects of CP55,940 in the triad assay, may be
predictive of antinociceptive activity in the CCI model of neuropathic pain. However, this
relationship does not extend to the drug discrimination paradigm. GAT211 which has been
shown to produce antiallodynic effects in a CIPN model of neuropathic pain at a dose of 20
mg/kg (Slivicki et al 2018) did not potentiate the discriminative stimulus effects of CP55,940
and also had no effect on response rates even at 40 mg/kg. As expected for CB1 PAMs, neither
GAT211, LDK1747, nor LDK1752 substituted for the discriminative stimulus of CP55,940. Of
these compounds only LDK1752 potentiated the CP55,940 discriminative stimulus. This result
was surprising considering LDK1752 had only a minor effect in the triad assay and lacked any
effects in CCI or the tetrad assay. Additionally, GAT211 which behaved as a PAM in the triad
assay failed to do so in drug discrimination. Taken together, these results suggest that
antiallodynic activity in CCI is not correlated with PAM activity in the triad assay and drug
discrimination paradigm.
The disparate effects of ZCZ011 analogs in vivo merits discussion on the separate
neurological mechanisms which govern the behaviors each measured in CCI, tetrad, and drug
discrimination. The CCI model and tail-flick test of the tetrad assay are both measures of pain

and so both involve pathways mediating pain transmission and modulation. The drug
discrimination paradigm, however, is a measure of subjective drug effects and is performed in
the absence of painful stimuli. The discriminative stimulus effects of a drug involve a
combination of sensory and affective components, either of which can be modulated to produce
antinociception. Whether the antiallodynic or antinociceptive properties of a drug depends more
on its modulation of the sensory or affective components of pain may also affect its
discriminative stimulus properties. That is to say selective modulation of pathways mediating the
sensory or affective components of pain may explain why antiallodynic analogs of ZCZ011 such
as GAT211 have no effect in the drug discrimination paradigm. Additionally, it is known that
models of neuropathic pain can lead to phenotypic alterations in CB1 receptor and
endocannabinoid levels (Ignatowska-Jankowska et al. 2015; Petrosino et al. 2007; Siegling et al.
2001). Therefore, it is possible that the CCI surgery could lead to changes in the subjective
responding of mice to CP55,940 which could produce different results for ZCZ011 analogs in
drug discrimination.
At the receptor level, there may be pharmacodynamic differences between ZCZ011
analogs. The activity of ZCZ011 analogs in vivo may differ depending on the orthosteric probe
being coadministered. The analogs examined in this study were tested using CP55,940 whereas
ZCZ011 has previously been tested in combination with AEA in FAAH (-/-) mice as well as in
combination with CP55,940 in C57BL6/J mice (Ignatowska-Jankwoska et al. 2015). Every
compound was shown to have some effect in combination with CP55,940 in the triad assay
suggesting that each compound reaches the CNS within the time points tested to produce a
measurable interaction with CP55,940. No conclusion can be made however without quantifying
drug levels in CNS as there remains the possibility of peripheral mechanisms of action.

In the CCI model, the effects of ZCZ011 are presumed to be mediated through
enhancement of endocannabinoid signaling at CB1 receptors (Ignatowska-Jankowska et al.
2015). Upregulation of the endocannabinoid system with respect to AEA or 2-AG levels as well
as CB1 receptor expression is known to occur in response to neuropathic pain (Petrosino et al.
2007; Siegling et al. 2001). Thus, for ZCZ011, ABD1236, and GAT211, their antiallodynic
effects may depend on increased endocannabinoid tone that results from the neuropathic pain
state induced in the CCI model. Accordingly, the CB1 PAM may enhance the signaling of AEA
and/or 2-AG at CB1 receptors. Alternatively, these modulators may act as allosteric agonists.
Based on in vitro data, analogs of ZCZ011 possess some intrinsic agonist activity at CB1
receptors. Studies on GAT211 have shown that its (R)- and (S)-isomers GAT228 and GAT229,
respectively, bind to distinct allosteric sites on CB1 receptors where GAT228 behaves as an
allosteric agonist and GAT229 is a PAM (Hurst et al. 2019; Laprairie et al. 2017). ZCZ011 and
ABD1236 also feature a chiral center, which is lacking in the LDK series of compounds. Most
LDK compounds are comparable to ZCZ011 in inhibition of cAMP accumulation and so the
structural differences do not significantly affect this activity. None of the compounds tested
behaved in a similar fashion as CB1 orthosteric agonist in the tetrad assay or drug discrimination
paradigm. This result could be a function of dose in that some compounds may have CB1 agonist
activity, but not at the doses tested. The potency of ZCZ011 analogs in vitro were significantly
lower in comparison to CP55,940 so it is likely that a dose of 40 mg/kg did not result in drug
concentration sufficient for agonist effects in vivo. LDK1729 produced small but significant
effects on locomotor activity and body temperature; however, it did not produce significant
effects in all four tetrad measures. A compound would need to induce all four tetrad effects to be
considered a cannabinoid agonist. None of the compounds tested in this study substituted for the

discriminative stimulus effects of CP55,940 in the drug discrimination paradigm. The allosteric
agonist activity of ZCZ011 analogs does not predict agonist activity in vivo. The extent however
to which ZCZ011 analogs function as PAMs or allosteric agonists may result in differences in
PAM activity in vivo. Differential activity at CB1 receptor sites which mediate PAM or allosteric
agonist effects may contribute to differences between ZCZ011 analogs in the triad and drug
discrimination assay. For example, only ZCZ011 potentiated the effects of CP55,940 in all three
measures of the triad assay whereas the other analogs only potentiated a subset of those effects.
To attribute differences in activity in vivo to activity at specific binding sites however would
require site-directed mutagenesis and transgenic expression of CB1 receptors.
In the triad and drug discrimination paradigms, only CP55,940 was used as an exogenous
CB1 orthosteric agonist. It is difficult to draw comparisons among these two assays and the CCI
model for several reasons. First, in the CCI model, although ZCZ011 may augment
endocannabinoid signaling through its actions as a CB1 PAM, the concentration of
endocannabinoids at CB1 receptors is unknown. AEA or 2-AG could have been used in the tetrad
and drug discrimination studies however it would be draw comparisons between assays in which
the orthosteric agonists at work are administered exogenously or produced endogenously. The
second reason is that neuropathic pain and antiallodynic effects in CCI are dependent on specific
pathways which modulate pain. Drug discrimination is a measure of subjective drug effects and
so has more to do with the affective component of cannabinoid-related behaviors. With respect
to pain however, there is a sensory component in addition to the affective component. Therefore,
CB1 PAMs may have a differential effect on the overt and subjective effects of cannabinoids.
That is to say CB1 PAMs may affect only a subset of cannabinoid-related behaviors. GAT211
potentiates the effects of CP55,940 in the triad assay but does not alter the potency of its

discriminative stimulus. LDK1752 potentiated the discriminative stimulus of CP55,940 but had
very little effect on its potency in the triad assay. Overall, the 2-phenyl indole class of CB1
PAMs show differential modulation of the antiallodynic, overt-behavioral, and subjective drug
effects of cannabinoids as measured in the CCI model of neuropathic pain, tetrad assay, and drug
discrimination paradigm, respectively.

Limitations
The first limitation of this study is that only CP55,940 was used as the orthosteric probe
to study the effects of CB1 PAMs. ZCZ011 has been characterized in the triad assay and drug
discrimination paradigm with both AEA and CP55,940 and there are ligand specific effects. In
the triad assay, ZCZ011 potentiates the effect of CP55,940 in all three measures whereas it only
potentiates the hypothermic effects of AEA (Ignatowska-Jankowska et al. 2015). Therefore,
differences in activity compared to ZCZ011 or a total lack of activity for the other analogs may
be attributed to ligand-dependent effects. Using either endocannabinoid AEA or 2-AG would
have better allowed for comparison to CCI results wherein the mechanism of action of CB1
PAMs are endocannabinoid-dependent. If ZCZ011 reduces CCI-induced mechanical allodynia
by potentiating endocannabinoid signaling at CB1 receptors, then an endocannabinoid ligand
should have been used in the triad assay and drug discrimination paradigm. The same applies for
the in vitro characterization as it would be beneficial to know whether any ZCZ011 analogs
exhibit ligand bias towards endogenous or exogenous cannabinoids. Doing so could help control
for ligand-dependent effects however the difference still remains that in CCI the
endocannabinoids would be produced endogenously rather than administered exogenously. The
challenge however with studying the endocannabinoids is that AEA and 2-AG are rapidly

hydrolyzed in vivo. AEA has been studied successfully with the use of FAAH (-/-) mice.
Although MAGL (-/-) mice can be generated for study, they present some confounds in that they
exhibit reduced CB1 receptor expression and function as well as anxiety-like behaviors (Deng et
al. 2020; Imperatore et al. 2015; Schlosburg et al. 2010).
In relation to the allosteric ligands, it is not known precisely how each interacts with CB1
receptors. Structural and in vitro data suggest the isomers of GAT211 bind at distinct sites to
mediate either PAM or allosteric agonist effects. Applying site-directed mutagenesis to CB1
receptors and expressing those receptors in transgenic mice could offer a model to compare
ZCZ011 analogs in terms of their CB1 binding interactions. The differences seen in vivo between
the ZCZ011 analogs may depend on which binding sites are occupied and which residues are
involved in binding.
Another limitation in this study was in relation to dose selection. No effect was seen for
GAT211 or LDK1747 at 40 mg/kg in drug discrimination and so it’s possible a higher dose
could have had an effect however solubility then becomes an issue. A dose of 40 mg/kg for a
ZCZ011 analog is approximately 10mM in terms of concentration. Studies on ZCZ011 in vitro
used concentrations no higher than 1𝝁M which potentiated the pharmacological effects of AEA
and CP55,940 (Ignatowska-Janowksa et al. 2015). Thus, it seems 40 mg/kg of a ZCZ011 analog
should be sufficient to produce PAM effects however the exact concentration achieved at CB1
receptors in vivo is unknown. Regardless, using another analog and having to exceed the dose of
ZCZ011 which reverses allodynia would make that compound less relevant from a therapeutic
standpoint and so it is perhaps unnecessary to test doses higher than 40 mg/kg.
Lastly this study was limited in the compounds available for study such as ABD1236
which could not be obtained. ABD1236 was among the three compounds which exhibited

antiallodynic activity in CCI and PAM activity in the triad assay (along with ZCZ011 and
GAT211). Therefore, it would have been beneficial in testing the hypothesis to evaluate
ABD1236 in the drug discrimination paradigm. LDK1729 and LDK1730 similarly remain to be
evaluated in drug discrimination with CP55,940. Despite this limitation there appears to be
sufficient evidence that the pharmacological effects of ZCZ011 analogs in vitro and in vivo do
not predict their antinociceptive effects in the CCI model of neuropathic pain.

Future Directions
Future directions for this study involve characterization of the remaining ZCZ011
analogs (ABD1236, LDK1729, LDK1730) in the drug discrimination paradigm. It would be of
interest to test whether ABD1236 potentiates CP55,940 dose-response generalization curve in
drug discrimination. Further experimentation in drug discrimination could be done using either
AEA in FAAH (-/-) mice or MAGL inhibitors in C57BL6/J mice to examine whether ZCZ011
analogs differentially potentiate the subjective effects of either endocannabinoid. This
experiment could help evaluate probe dependence for ZCZ011 analogs in drug discrimination.
For the compounds evaluated in this study (GAT211, LDK1747, LDK1752), 40 mg/kg was the
highest dose used and so future studies should examine whether these compounds alter the
discriminative stimulus properties of CP55,940 at higher doses. An interesting question which
arises from this study is whether any changes in the endocannabinoid system induced by CCI
surgery alter the overt or subjective effects of cannabinoids as measured in the tetrad assay and
drug discrimination paradigm. In other words, it is not known whether the CCI model produces
any changes in the endocannabinoid system which modulate non-pain-related behaviors. If
sciatic nerve injury in the CCI model results in an upregulation of the endocannabinoid system

that enhances the sensory component of pain modulation, it may also produce changes in the
affective component of cannabinoid-related behaviors. To test this hypothesis, it would require
combining the CCI model with the drug discrimination paradigm in such a way that one can
assess whether the CCI surgery alters the discriminative stimulus properties of a CB1 orthosteric
agonist. To do this would require obtaining a dose-response for a CB1 agonist in drug-like
responding and response rates then subjecting that cohort of animals to the CCI surgery or a
sham surgery and see whether the dose-response relationships are altered. Subsequent to the
surgery would be re-constructing the same dose-response curves to see if the CCI surgery
produced any leftward or rightward shifts in CB1 agonist potency and whether that effect was any
different from the sham surgery group. A challenge to this model would be that in the weeks it
takes to build a dose-response curve in drug discrimination, the pain response thresholds of the
mice would increase over time as they healed, making the model inconsistent. This problem
could be overcome by using a between-subjects design, however that would require more
subjects. Another question to examine in the future is whether the hypothesis holds true for a
separate class of CB1 PAMs that are structurally distinct from the 2-phenyl indoles represented
by ZCZ011.

Conclusion
The purpose of this study was to examine the relationship between CB1 PAMs in the CCI
model of neuropathic pain, tetrad assay, and drug discrimination paradigm. The results of this
study indicate that there is no correlation for CB1 PAM activity between the three behavioral
paradigms. The pathways which mediate the overt and subjective effects of cannabinoids are
separate and distinct to the extent that compounds in the same class of CB1 PAMs exhibit

activity which does not always translate between behavioral measures in vivo. The tetrad and
drug discrimination paradigms are useful for inferring cannabimimetic effects and have been
used to infer potential abuse liability of CB1 receptor ligands administered alone. However, the
results from studies investigating CB1 PAMs in combination with CP55,940 in these assays did
not predict efficacy in predicting antiallodynic effects in the CCI model. Similarly, a CB1 PAM
which is effective in the CCI model may exhibit no PAM activity in the tetrad or drug
discrimination assays in that they do not potentiate the dose-response relationships of orthosteric
agonists; GAT211 is one such example. For CB1 receptor ligands tested in the CCI model of
neuropathic pain, it remains important to assess those compounds in tetrad and drug
discrimination to rule out any possible psychoactive effects. Thus, all three measures should be
employed when studying the in vivo pharmacological effects of CB1 receptor ligands. Although
the triad and drug discrimination assays do not appear to not offer a means to predict
antinociceptive effects in the CCI neuropathic pain model, these assays possess utility to
investigate the efficacy of CB1 ago-PAMs in neuropathic pain models, which lack
cannabimimetic side effects associated with CB1 orthosteric agonists. Nevertheless, for ligands
acting at CB1 receptors, the tetrad assay and drug discrimination paradigm should still be
employed to screen for abuse liability. These assays are also required from a mechanistic
standpoint. The CCI model does not yield any information about the mechanism of action of
ZCZ011 analogs and whether they are acting as an agonist or PAM at CB1 receptors. The tetrad
and drug discrimination paradigms therefore represent an indispensable tool to pharmacologists
studying the effects of CB1 PAMs.
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